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Summary 
The research on atherosclerosis therapy is ongoing for decades. This thesis is focused on 
lesions where interventional treatment is required, with special focus on stents. For care of 
late stage atherosclerosis two things are of high importance: first to exclude the diseased 
tissue and second to renew a healthy surface of endothelial cells. Nowadays, there is no 
treatment, except for vessel replacement, which guarantees those issues. Addressing those 
issues I hypothesize that a viable stent structure based on a tissue covered stent will prevent 
thrombocyte adhesion and hyperplasia. 
The aim of this study is to construct a tissue-covered endothelialized stent, the BioStent, and 
prove the hemocompatibility in vivo. Tissue engineering gives the chance to create new and 
healthy tissue which can replace the native one where it is damaged. By combining stents 
with tissue engineering, the stent is surrounded by autologous tissue and therefore on the 
one hand the foreign object reaction is avoided and on the other hand the damaged tissue is 
replaced by a new healthy tissue layer. The most important advantage is the endothelial 
layer with its known and important role of anti-thrombotic and anti-coagulative function, 
lining the lumen of the stent.  
For evaluation, different scaffolds (fibrin, elastin-like recombinamers), cell types (endothelial 
cells, endothelial progenitor cells) and stents (warp knitted, braided) were tested in vitro. For 
in vivo test, a warp knitted nitinol stent covered with fibrin-gel and EC was implanted in 5 
sheep for 3 months.  
The stent structure was not strong enough to completely expand inside the vessel. Therefore 
the stents were implanted as interponate for in vivo evaluation. The precrimped BioStent 
proved to be implantable in carotid position over three months. Furthermore, the important 
crimping process could be performed without clinical relevant damage. The stent evidenced 
patency in four of five sheep over the planned implantation time of three months. The tissue 
analysis showed healthy tissue formation and a confluent endothelial layer orientated to the 
blood flow.  
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Zusammenfassung 
Die Behandlung der Arteriosklerose steht schon seit Jahrzehnten im Fokus der Forschung. 
Die vorliegende Arbeit legt ein besonderes Augenmerk auf die Anwendung von Stents bei 
Läsionen, die eine invasive Behandlung erforderlich machen. Bei der Behandlung 
fortgeschrittener Arteriosklerose sind zwei Dinge von größter Bedeutung: erstens die 
Exklusion des geschädigten Gewebes und zweitens die Wiederherstellung eines intakten 
Endothels. Derzeit gibt es keine derartige Behandlung, ausgenommen dem Ersatz durch ein 
natives Blutgefäß. Die Hypothese, dass eine vitale, mit Gewebe umschlossene Stentstruktur 
vor Thrombozytenadhäsion und Hyperplasie schützt, soll in der vorliegenden Arbeit 
überprüft werden.  
Das Ziel dieser Studie ist die Konstruktion eines gewebeumschlossenen, endothelialisierten 
Stents, dem BioStent, und der Beweis der Hämokompatibilität im in-vivo-Experiment im 
Schaf. Das Tissue-Engineering ermöglicht die Herstellung neuen und gesunden Gewebes, 
welches das geschädigte Gewebe ersetzen kann. In der Kombination mit einem Stent wird 
dieser mit autologem Gewebe umschlossen, dadurch die Fremdkörperreaktion umgangen 
und die geschädigte Region durch gesundes Gewebe überdeckt. 
Die wichtigste Komponente des BioStents ist die Endothelzellschicht im Lumen, mit den 
bekannten antithrombotischen und antikoagulativen Funktionen. Zur Evaluierung des 
BioStents wurden verschiedene Scaffolds (Fibrin, Elastin-Like Recombinamers), Zellquellen 
(Endothelzellen, endotheliale Progenitorzellen) und Stents (gewirkt, geflochten) in vitro 
getestet. Für die in-vivo-Experimente wurden gewirkte Stents aus Nitinol, beschichtet mit 
Fibringel und Endothelzellen, in fünf Schafen für drei Monate implantiert.  
Die radiale Steifigkeit der getesteten Stentstrukturen war für eine vollständige Expansion im 
Blutgefäß noch nicht ausreichend, daher wurde eine Implantation als Interponat gewählt. 
Vor Implantation wurde der Biostent gekrimpt und expandiert um die Belastung des 
Krimpens bei einer herkömmlichen Implantation zu simulieren. Der wichtige Krimp-Prozess 
verursachte keine klinisch relevanten Schäden. Nach einer geplanten Implantationszeit von 
drei Monaten wiesen vier von fünf Schafe einen durchgängigen Stent ohne Ablagerungen 
auf. Die Gewebeanalyse zeigte eine gesunde Gewebeformation und einen konfluenten 
Endothelzell-Layer mit zum Blutfluss orientierten Zellen. 
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1 Introduction 
In our demographically changing world cardiovascular diseases are a big topic and there is a 
growing need for reliable therapy. Atherosclerosis is a big issue for thousands of people 
worldwide. They suffer from narrowed vessels and ischemia to stroke and heart attack. To 
improve their life quality surgery is needed.  
Since about 60 years(1), surgeons are able to replace the blocked arteries using native 
vessels of the patient or, in absence of those, synthetic grafts. Later on, stents, which can be 
implanted minimal invasively and keep the vessel open, came on market. Sadly, this solution 
lasts only a few years. Most of the stents are blocked within three years. The problem with 
stent treatment is the remaining damaged vessel region and injured endothelial layer. There 
are several stents using drug delivery to address the body reaction to prevent restenosis, but 
still, restenosis is one of the biggest problems in vascular surgery and reoperations are 
required.  
A functional endothelium is essential for survival. Besides its barrier function and exchange 
of nutrients and waste products, it prevents the blood vessel system from calcification and 
thrombosis. Without endothelial cells, accelerated arteriosclerosis occurs where it is not 
repaired fast enough. 
Announcing the problem of restenosis, researchers are working on several kinds of improved 
stents. One promising method is to use the advantages of tissue engineering: combining the 
mechanical properties of stent technology with autologous tissue growth for coverage. In 
this thesis, a completely covered stent in autologous tissue was developed and tested in vivo 
for the first time. The advantage of this stent graft is on the one hand the total occlusion of 
the plaque and on the other hand the autologous and functional endothelial lining of the 
surface. 
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1.1 Principle of blood vessels 
There are about 100,000 km of blood vessels inside the human body, supplying the system 
with nutrients and removal of waste products. The heart pumps 5 liters of blood per minute, 
with 80 mmHg referring to diastolic and 120 mmHg to systolic blood pressure. The arteries 
deliver well-oxygenated blood from the heart to the tissue, whereas the veins collect and 
return deoxygenated blood back to the heart(2). Caused by the different size and position of 
the blood vessels the flow rate varies from 30 cm/s close to the heart down to 0.02 cm/s in 
capillaries.  
 
1.1.1 General anatomy  
The general anatomy of blood vessels is assembled by three layers. There is the tunica 
adventitia, the outermost layer, followed by the tunica media and the tunica intima in the 
inside. The tunica intima is lined by the endothelial cells (figure 1).  
The adventitia, also called tunica externa, is based on connective tissue and collagen fibers. 
It also contains smooth muscles and some elastin fibers. The main function is to stabilize the 
vessels inside the tissue.  
The media contains the membrane elastica externa, the elastic connective tissue and muscle 
cells. The smooth muscles are orientated in several sheets, circular around the vessel. In 
large arteries also longitudinal oriented muscles are placed. The circular muscles are 
involved in vasoconstriction and vasodilation. During vasoconstriction (systole) the vessels 
are contracted and the diameter is narrowed. In contrast, the lumen is dilated during 
relaxation of the vessels at the vasodilation (diastole). The intima is based on the membrane 
elastica interna which is covered by the endothelial cells which form a smooth monolayer 
called endothelium(3). There are differences in the vessel structure based on the needs of 
the vessel, but all vessels are lined with endothelial cells, from the largest arteries to the 
smallest capillaries.  
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Figure 1: Blood vessel structure. The general anatomy of blood vessels is defined, from 
inside to outside, by the tunica intima, media and adventitia. The intima contains the basal 
membrane and the endothelial cells. The media is based on elastic connective tissue and 
muscle cells. The adventitia is based on connective tissue and collagen fibers and also 
contains smooth muscles and some elastin fibers. The structure of the arteries, veins and 
capillaries is different due to their size and function. Arteries contain a much thicker tunica 
compared to veins. Capillaries only consist out of the endothelium, the interna and the 
basal membrane. 
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1.1.2 Arteries, veins and capillaries 
The shape and structure of blood vessels varies depending on the position of the vessel in 
the circular system. Starting at the heart, large arteries transport the oxygenized blood to 
the body. From the large arteries smaller branches, the arterioles, spread further and 
subdivide to very small structures, the capillaries. The capillaries fuse to larger venules which 
lead into the veins, bringing the blood back to the heart. The blood pressure is highest in the 
aorta and drops along the system.  
Although the general anatomy of the blood vessels is common, there are some differences 
between arteries, veins and capillaries suited to their function (figure 1)(4). The arteries 
consist of several well defined layers. The central layer (tunica media) a large layer 
containing smooth muscles is placed between two thinner elastic layers, enabling the 
bulging of larger arteries. This is necessary to provide a continuous blood flow. 
The arteries can be subdivided into the elastic arteries, the muscular arteries and the 
arterioles. The elastic arteries, also known as conducting arteries, are the largest with a 
diameter of up to 2.5 cm. They contain a dense elastic fiber structure due to their conductive 
function. The muscular arteries, also distribution arteries, contain more smooth muscles in 
the media and are smaller with a diameter of 0.4 cm. The higher muscle part is due to their 
distributional function. The smallest arteries with 30 µm in diameter are the arterioles which 
have a thick muscular media. They are also known as resistance vessels which play an 
important role for blood pressure control. By contraction or relaxation the diameter can 
shrink or enlarge to control blood pressure and distribution. 
Veins, in general, have thinner walls compared to the arteries correlated to the lower 
pressure they have to deal with. While in arteries the media is the thickest layer, in veins the 
adventitia is the dominant layer. The veins are transport tubes with large diameter and low 
resistance. Additional valves prevent backflow for example in the legs. The smaller venules 
are the connection between the capillaries and the veins. Those vessels are small with a very 
thin wall and some solute diffusion ability. 
The smallest vessels are the capillaries. Capillaries are based on a thin connective tissue lined 
with endothelial cells. The vessel walls are very thin to allow an exchange of nutrients and 
Introduction 
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waste products between the blood and the tissue, which is the main task of the blood 
system(5). 
1.2 Atherosclerosis 
Atherosclerosis „is defined as a focal, inflammatory fibro-proliferative response to multiple 
forms of endothelial injury”(6), leading to vessel narrowing or total vessel occlusion. In 
consequence, the tissue and organs are undersupplied with oxygen and nutrients, which 
could lead to loss of organs or, in case of the coronary artery, it leads to a heart attack.  
Atherosclerosis is a disease mainly found with elderly people. Due to the demographic 
change, there is an increase in diseased people expected. Besides the age, way of life 
influences the disease. Typical risk factors of life style are lack of exercise, overweight and 
smoking. Further risk factors contributed to the health situation are hyper-/dyslipidemia, 
high blood pressure, diabetes, genetical disposition and age (Table 1). In figure 2, the 
influence of the most important risk factors is visualized by the size of the arrows. 
 
Table 1: Atherosclerosis risk factors(6). 
Lifestyle Health situation 
 Lack of exercise  Hyper-/dyslipidemia 
 Overweight  High blood pressure 
 Smoking  Diabetes 
  Genetical dispositon 
  Age 
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Figure 2: The influence of risk factors is shown correlated to the arrow size. From highest 
to lowest - risk factors for critical limb ischemia are: diabetes, smoking, low ankle brachial 
pressure Index (ABPI), an age above 65 and lipid abnormalities triglycerides. CLI = critical 
limb ischemia (7). Reprinted from the Journal of Vascular Surgery 45, L. Norgren, W.R. 
Hiatt, J.A. Dormandy, M.R. Nehler, K.A. Harris, F.G.R. Fowkes, Inter-Society Consensus for 
the Management of Peripheral Arterial Disease (TASC II), page 10 (2007), with permission 
from Elsevier. 
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1.2.1 Stages of atherosclerosis 
Atherosclerosis can be defined in six stages. The first symptom-free stages can already start 
during early childhood. The lesions’ development can change in time depending on lifestyle 
(see risk factors above). In figure 3 the process is schematically shown. 
 
 
Figure 3: Atherosclerosis steps. A: normal healthy artery; B: initial steps of atherosclerosis 
including blood monocyte adhesion and migration into the intima, maturation of 
monocytes into macrophages and further into foam cells; C: lesion progression including 
smooth muscle cell (SMC ) migration into the intima, proliferation of SMCs and increased 
extra cellular matrix (ECM) production; D: fracture of the plaque's fibrous cap and 
thrombus formation(8). Reprinted with permission from Macmillan Publishers Ltd: Nature 
473, Peter Libby, Paul M Ridker, Göran K. Hansson, Progress and challenges in translating 
the biology of atherosclerosis, copyright (2011) 
 
A B 
C D 
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Lesion type I: 
As the first stage, in lesion I, only small lipid depositions are found accompanied by some 
foam cells and intimal thickening. Type I lesions are already found in children or in very little 
stressed vessels of adults (figure 3 B). 
 
Lesion type II: 
The lesion type II is usually found in the age of puberty. It is indicated by increased numbers 
of foam cells which are oriented in layers. Fat deposition is accomplished in the smooth 
muscle cells in the intima. Furthermore T-lymphocytes and mast cells are found. Besides the 
intracellular fat deposition, also fatty streaks and fat congregations are seen on the 
periphery of the blood vessel. Those peripheral fat depositions are oriented to the blood 
flow. The type II lesion is distinguished in type IIa thickening of the intima with progression 
risk and type IIb without progression risk. 
 
Lesion type III: 
The type III lesion is the link between the inconspicuous first lesions and the conspicuous 
later lesion types. At this point the first extracellular lipid depositions are detected. 
Furthermore there are fat congregates surrounding the smooth muscle cells in the intima. 
 
Lesion type IV: 
The advanced lesion type IV is marked by the cell free fat congregation the so called 
atheroma. The atheroma developed by lipoprotein deposition and degradation of the foam 
cells. Additionally the extracellular lipids accumulate. Between those fat lakes and the 
endothelial surface macrophages, smooth muscle cells, lymphocytes and mast cells are 
enclosed. Because of collagen absence and higher wall tension the risk of rupture is 
increased. A further characteristic of type IV is a first grow of capillaries inside the plaque. 
For blood flow maintenance the vessel is reconstructed to leave the lumen nearly in the 
original size but the wall of the artery dilates to accommodate the plaque (figure 3 C).  
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Lesion type V: 
Characteristic for lesion type V is a fibrous binding tissue above the atheroma, also called 
fibrosis. The fibrosis is based on a higher proliferation rate of the muscle cells, which 
additional expresses extra cellular matrix molecules, like collagen and proteoglycans. Some 
of the muscle cells differentiate to fibroblasts. Instead of contractile filaments those cells 
show rough endoplasmic reticulum. The capillaries, already seen in type IV, are increased in 
lesion V. Three subgroups (Va-c) are defined by several markups. Lesion Va also called 
fibroatherom lesion shows a lipid pool. Lesion Vb shows also a lipid pool with additional 
calcifications. There is no lipid pool seen in lesion Vc which is less fatty but is a very 
fibrinogen rich intima lesion. The fibrinogen stimulates the proliferation of smooth muscle 
cells. Both lesion IV and V can develop hematomas and thrombosis. 
 
Lesion type VI: 
In elderly people more complex lesions of type IV and V occur. Those are classified as lesions 
type VI. The causes are mainly plaque rupture, fissures, erosions and ulcerations of the 
subendothelial fibrous tissue. Three types are distinguished. Type VIa shows a ruptured 
surface, type Vb involves hematomas or bleeding and type Vc indicates thrombosis. Also 
combinations of the subgroups are possible (figure 3 D).  
 
1.2.2 Atherosclerosis statistics 
Cardio vascular disease (CVD) is one of the main causes of death in the western world (figure 
4). 49 % of CVDs are caused by coronary heart disease, which alone caused about 1 of 6 
deaths in the United States in 2009(9). Coronary heart disease is the most common reason 
for heart failure (figure 5). Also the peripheral artery disease is often underestimated, but 
still causes 3.4 % of CV deaths in the United States. In Germany more than 4.5 million people 
suffer from peripheral artery occlusion disease (PAOD). Every fifth person aged above 65 
years is affected(10). 
 
Introduction 
23 
 
 
 
Figure 4: The percentage breakdown of deaths, attributable to cardiovascular disease, of 
the United States in 2009. With 49 % coronary heart disease is the largest cause of deaths. 
Source: National cause(9). Reprinted from Circulation 127, Alan S. Go, Dariush 
Mozaffarian, Véronique L. Roger, Emelia J. Benjamin, Jarett D. Berry, William B. Borden, 
Dawn M. Bravata, Shifan Dai, Earl S. Ford, Caroline S. Fox, Sheila Franco, Heather J. 
Fullerton, Cathleen Gillespie, Susan M. Hailpern, John A. Heit, Virginia J. Howard, Mark D. 
Huffman, Brett M. Kissela, Steven J. Kittner, Daniel T. Lackland, Judith H. Lichtman, Lynda 
D. Lisabeth, David Magid, Gregory M. Marcus, Ariane Marelli, David B. Matchar, Darren K. 
McGuire, Emile R. Mohler, Claudia et al. Heart disease and stroke statistics–2013 update: a 
report from the American Heart Association., page 122 (2013), with permission from 
Wolters Kluwer Health. 
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Figure 5: Percentage of artery disease classified into coronary artery disease (44.6 %), 
cerebral artery disease (16.6 %) and peripheral arterial disease (PAD) (4.7 %), based on 
REACH data(7). Reprinted from the Journal of Vascular Surgery 45, L. Norgren, W.R. Hiatt, 
J.A. Dormandy, M.R. Nehler, K.A. Harris, F.G.R. Fowkes, Inter-Society Consensus for the 
Management of Peripheral Arterial Disease (TASC II), page 12 (2007), with permission from 
Elsevier. 
 
1.3 Atherosclerosis treatment 
Cardiovascular diseases are one of the main causes of death in the economic world(11). An 
early prevention by addressing the risk factors would be best. The most important part is to 
lower obesity(12). Obesity affects also the blood pressure, lipid proliferation, glucose 
metabolism, inflammation and atherothrombotic disease progression. Nevertheless, 
preventional treatment needs to be started at an early stage(12). The reduction in 
cardiovascular events can be additionally achieved by pharmacological treatment. 
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Treatment with 3-hydroxy-3methylglutaryl coenzyme A showed significant reduction in 
cardiovascular events in long and short outcomes(13). In asymptomatic patients medical 
therapy shows definitive evidence for disease management, nevertheless in symptomatic 
disease interventional treatment might be necessary(14). Succeeding, the focus will be on 
interventional treatments. 
Different interventional procedures are possible to treat atherosclerosis. There is balloon 
dilatation, stenting and vessel replacement. The advantages and disadvantages of each 
treatment are shown in table 2. Focused on the long outcome results, the vessel 
replacement by a native vessel is the most likely intervention. However, a healthy vessel is 
not always available. Furthermore, the surgical operation is not an option for all patients. An 
open surgical treatment carries a mortality rate of up to 4.4 %(15). Based on the patient’s 
age and health status, as well as the position of the blocked vessel, a surgical intervention, 
can be too high of risk. Less stressing for the body are percutaneous interventions like 
balloon angioplasty or stent implantation. 
 
Table 2: Atherosclerosis intervention: advantages and disadvantages. 
Intervention Advantages Disadvantages 
Balloon dilatation Percutaneous, minimal 
invasive 
Bad long outcomes 
Stenting  Percutaneous, minimal 
invasive, increased patency 
rate 
early stent thrombosis in 
BMS and late stent 
thrombosis in DES 
Vessel replacement Good long-term outcomes 
with autologous implants 
Not minimal invasive, 
limited availability of 
autologous implants,  
restenosis in artificial 
implants 
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The amount of catheterizations rose enormously in the last decades. The balloon dilatation, 
also known as percutaneous transluminal angioplasty (PTA), is very easy to perform and, 
especially in the lower limp region, an often used method. After a good patency rate right 
after dilatation (95 %), the vessel narrows again (42-55 % after 5 years) and retreatment is 
needed(16). 
The success rate of stents shows better long-term results caused by the mechanical opening 
of the vessel. Therefore it is not surprising that the total rate of cardiac stent procedures 
rose by 61 % from 1999 to 2006. In 2006 first publication about late stent thrombosis in drug 
eluting stents (DES) came up. So the procedure rate declined by 27 % between 2006 and 
2009(17). Nevertheless, the implantation number of DES rose continuously in the last years.  
 
 
 
Figure 6: Amount of cardiovascular treatment in Germany from 2005-2013 (per 10,000 
insurance years). The blue line shows the used bare metal stents, red the drug eluting 
stents (DES), green the bypass operations and the balloon dilation in blue. There is an 
increase of DESs used in the last years, whereas the bare metal stents (BMS) decreased in 
equal measure. The bypass operations and the balloon dilatations stayed almost constant 
at low level. The diagram is based on data of statista (18). 
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Figure 6 gives an overview of the amount of cardiovascular treatment in Germany from 
2005-2013. Shown are the interventions per 10,000 insurance years. There is nearly no 
change in the operation numbers for bypass operations and balloon dilations over the last 
decade. For the BMS and DES the total number increased over time, but the ratio changed. 
Also there is a fallback for DES after 2006 the number increased drastically afterwards. In 
2010 the numbers were almost equal and in 2013 the number of DES in more than fourfold. 
 
For coronary intervention stents are used in 90-95 % of cases(19), in peripheral vascular 
interventions stents are used in nearly 50 % (20).  
By having an improved opening time compared to the angioplasty and a better availability 
and less invasive intervention as the vessel replacement, the stents are most promising. 
Therefore it is not surprising that in the last decades a lot of different stents hit the market 
and also a lot of new interventions are discussed in research. Further on, the focus will be on 
stents for atherosclerosis intervention. 
 
1.4 Stents for atherosclerosis treatment 
Stents can be characterized by expanding mechanism, their structure, cover material and cell 
or non-cell coating. The expanding mechanism can be divided in self-expandable and balloon 
expandable stents. 
There are different production types for stent development: mesh or spiral made by winding 
or knitting of wire, cut out of thin walled tubes, ring stents made of wire by soldering or 
fusion and braided stents made out of wires(21). Most common materials for stent 
construction are chromium-nickel-steel, cobaltoan-alloy, titanium-nickel (Nitinol), platinum-
iridium, titanium and tinanium-alloy(21). Besides those structural classifications, the stents 
are defined by their functional improvements (table 3).  
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Table 3: Overview of stent classifications. 
Stent Description / function Image 
Bare metal stent First stents made of 
metal, not degradable 
 
Drug eluting stent Coated with drug depots 
to prevent intima 
thickening and 
inflammation 
 
Biodegradable stents will degrade over time 
inside the body. 
Degradation products 
may not cause 
immunoreaction 
 
Covered stents wrapped with a 
degradable or non-
degradable material 
leading to a total 
occlusion of the plaque 
 
Cell capturing stents Coated with adhesion 
sequences to increase 
reendothelialization 
 
 
The first developed stents are the bare metal stents (BMS). Furthermore and often used, are 
the drug eluting stents (DES) which are covered with drugs. By drug release, cell 
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proliferation, intima thickening and thrombocyte adhesion can be addressed. One other 
growing group are the biodegradable stents, which degrade inside the body over time. With 
this concept no foreign body remains after initial stent therapy. Covered stents are 
completely wrapped with a second material to completely exclude the atherosclerotic 
plaque. The cover of the stent can be natural or synthetic. Of high interest are the cell-
capturing stents, which are coated with adhesion sequences to capture EPC and support 
reendothelialization. 
 
1.4.1 Bare metal & drug eluting stents 
The mainly used stents are bare metal stents (BMS) and drug eluting stents (DES). The first 
stents were BMS. Although the results were promising and much better compared to 
angioplasty alone, in about 20-40 % of cases in-stent-restenosis occur(22). The initial cause 
of restenosis is based on vascular smooth muscle cell proliferation and migration, which 
leads to neointima formation(23). As a consequence anti-proliferative drugs came to use in 
so called drug eluting stents, like the sirolimus eluting stent and the paclitaxel eluting stent. 
In early restenosis the DESs show better results compared to the BMSs, based on their 
controlled neointima formation(24). Nevertheless, late outcomes failed by delayed vascular 
healing(24),(25). Incomplete endothelialization was declared as a potential factor in acute 
stent thrombosis after DES intervention(26). It was found that uncovered stent struts, which 
leak of an endothelial cell layer, are the main cause of late and very late stent 
thrombosis(27). It is not surprising, knowing that endothelial cells are involved in providing a 
non-adherent surface for platelets and leukocytes, which results in there antithrombotic 
function(28). Nevertheless, in 2010 around 75 % of the implanted stents in percutaneous 
coronary intervention (PCI) were DES and only 25 % were BMS(17). There is a defined trend 
towards DES. The numbers of the last years showed a continual increase of DES and 
decrease of BMS implantation (see also Figure 6). 
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1.4.2 Biodegradable stents 
Besides metal stents a lot of effort was put into biodegradable stents. Typical materials are: 
polycaprolactone (PCL), polyglycolic acid (PLGA), poly(D,L-lactide/glycolide) copolymer 
(PDLA), poly-L-lactic acid (PLLA), magnesium and cobalt-chromium polymers.  
The concept of the degradable stents is to support the vessel only as long as needed. After 
vessel reconstruction the stent degrades without leaving any foreign object. One critical 
point is the optimal degradation rate. Depending on the material components, the 
degradation time of the stents varies from six month to over 24 month(29). Thereby the 
degradation rate correlates to the molecular weight, the surface quality and composition of 
the polymers(30). Another big issue are the resulting cleavage products. The cleavage 
products during degradation might irritate the surrounding tissue. For example PLGA based 
stents hydrolytically degrade into glycolic acid and lactic acid(30). This acid degradation 
might cause tissue irritation due to the pH decrease. One weakness of biodegradable stents 
is their mechanical properties. The materials are weaker compared to metal, which can be 
compensated by structure and material thickness. Nevertheless, there are already reports 
showing comparable results to metal stents(29–31). 
Common biodegradable stents are the Igaki Tamai Stent out of PLLA(32), the REVA stent 
(REVA Medical) a tyrosine-derived polycarbonate poxmer, the everoliumus-eluting stent 
(Bioabsorbable Vascular Solutions, Abbott ascular, CA-US), the tacrolimus-eluting cobalt-
chromium polymer stent (Mahoroba
TM
) and the magnesium stent(29). 
 
1.4.3 Covered stents 
Stents can be covered by synthetic or native materials. By coverage with elastic films the 
early neointima maturation should be prevented(25). For example, by coverage with 
expanded polytetrafluoroethylene (ePTFE) the support of the vessel and additional exclusion 
of the plaque was addressed. Although, the potential of improved patency because of 
decreased restenosis, has not been proven yet(15). 
One other option is to cover stents with native tissue in vitro before stent application. Like 
the pericardium covered stents “Over and Under” and “AneuGraft®”. Those two stents are 
currently in clinical study (SLEEVE I and II)(33). The first results of saphenous vein graft 
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stenosis treatment were promising. But sill there is a functional endothelial cell layer 
missing. The preseeding with endothelial cells is quiet more challenging. Therefore it is more 
often used in the vascular graft research than in the field of stent coverage.  
 
 
 
 
 
Figure 7: Autologous vein graft surrounded by a stent for vascular replacement in a 
nonhuman primate model (Chacma baboons); A: Vein-graft without stent showing the 
typical size mismatch, B: Vein-graft inside the stent adjusted to the artery size, C: Vane 
graft after 6 month of implantation, showing a high wall thickening, D: Vane-stent graft 
after 6 month of implantation showing no wall thickening(34). Reprinted form Journal of 
Vascular Surgery 54, Peter Zilla, Loven Moodley, Michael F. Wolf, Deon Bezuidenhout, 
Mazin S. Sirry, Nasser Rafiee, Wilhelm Lichtenberg, Melanie Black, Thomas Franz, Knitted 
nitinol represents a new generation of constrictive external vein graft meshes, page 1444–
1445, 2011, with permission from Elsevier. 
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Another interesting approach was performed by Zilla et al. They used an entire autologous 
vein surrounded by a stent for vascular replacement (Figure 7) (34). Here the stent is used as 
mechanical support for the vein. Compared to a vein interponate the hyperplasia of the 
intima was suppressed. Within this experiment the endothelial cells are already in their 
native environment and can perform well, right from the implantation time point. But for 
this type of stent an open operation is needed once for the vein harvesting and once for the 
vessel replacement.  
 
1.4.4 Cell capturing stents 
A confluent endothelial layer is addressed by capturing endothelial progenitor cells out of 
blood. Because the reendothelialization from the anastomosis is very limited,(11) a system 
to adhere the cells on the whole stent is very likely. One problem is the inconsistence of the 
EPCs, which vary from patient to patient and is dependent on the age(35). Also the ability to 
capture circulating EPCs is controversially discussed(24), (36), (37). A first EPC capturing stent 
(ECS) is on the market, the Genous Bio-engineered stent from OrbusNeich
TM
. The Genous 
stent proved feasibility and safety in the “HEALING-FIM study”(38). A further separate study 
(TRIAS HR) is ongoing. The 1 year evaluation shows no sufficient results for ECS compared to 
DES. There was a 17.4 % target lesion failure in ECS compared to 7.0 % in DES seen(39). The 
latest results are not available yet. With regard to the increased late thrombosis for DES the 
results for ECS are very interesting  
The Genous stent is coated with anti-CD34 antibodies for EPC capturing. Besides antibody 
adhesion also aptermer(40) based stents or RGD(41) covered stents are under research.  
A new method which does not use adhesion markers, but magnetic forces, was initiated by 
Uthamaraj et al.. Uthamraj used a novel ferromagnetic bare metal stent. For cell seeding EPC 
out of the patients blood were isolated three month before implantation. The cells were 
labeled with SPIION and CM-DiI. Immediately after stent placement the cells were inserted 
over the wire balloon catheter, inflated proximally to the stent. After 7 days of implantation 
in pig (n=4) endothelialization was verified using histological analysis. 
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1.4.5 Endothelial cell therapy 
There are some approaches which used only endothelial cells to treat arteriosclerosis 
directly. Endothelial cells were isolated and placed surgically perivascular in porcine arteries, 
resulting in a reduced intima thickening, stenosis and negative remodeling(42). In a next step 
a ultrasound guided percutaneous delivery placement was used to place endothelial cells in 
a stented artery of pig(43). Kipshidze et al. glued endothelial cells on rabbit arteries in vivo 
using fibrin glue. The results showed a significant reduction of restenosis in arteriosclerotic 
arteries although the coverage only achieved a 70 % confluency(44). 
Those trials showed a significant improvement, but are not suitable for every lesion. 
Furthermore, a lot of endothelial cells might be flushed away leading to an inappropriate 
coverage. 
 
1.4.6 Tissue engineered stents 
There are several approaches using tissue engineering in combination with stents. Nakayma 
et al.(25) implanted a stent molded on a silicon tube subcutaneously in pouches of rabbits. 
By this in-body tissue architecture the stent was surrounded by collagen and fibroblast 
coating within three months. Although the stent proved to be crimped and balloon dilated 
with only little damage to the tissue, no endothelial cell coating was done in this trial. Later 
an implantation study was performed in beagles over one month. The stents were covered 
using the in-body tissue architecture in one beagle for 4 weeks and implanted afterwards as 
an allograft into another beagle for one month. The results showed neither stenosis and 
aneurysm changes nor thrombus formation. A neointima formation on the whole stent was 
achieved. Although, there was no pre-seeding with endothelial cells the H&E staining 
showed some cells on the surface(45).  
L’Heureux and Mc Allister patented a tissue coated stent, based on a tissue sheet wrapped 
around the stent structure(46). By covering the stent a barrier against cell migration is 
achieved with additional reduction of the foreign body response. Furthermore, to reduce 
thrombosis, the fibroblast based sheet can be endothelialized afterwards. 
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Wolf, Yunker and Trescony patented a new seeding method for implantable medical devices 
such like vascular prosthesis(47). By rotating the prosthesis the axial centrifugation forces 
the cells to concentrate towards the luminal surface. With this method also coated stents 
could be endothelialized. The concept promise a implantation of the device shortly after 
seeding.  
 
The group of Matsuda worked on two devices of EPC-seeded intravascular stent devices(48). 
One was a photocured gelatin-coated metallic stent with an open stent structure and the 
other one was covered with a micro porous thin segmental polyurethane film coated with 
photocured gelatin. Both were seeded with canine EPC and evaluated in vitro. Either stent 
showed a confluent lining with EPC also after expanding. In a different approach the canine 
EPC were included in a hybrid tissue and mounted on a metallic stent(49). In vitro the EPC 
migrated to the surface of the coting to form a confluent cover over 7 days. 
 
Achneck proved a significant increased biocompatibility of Titanium cardiovascular devices 
by seeding with EPC(50). In a porcine in vivo study all EPC-seeded tubes remained patent 
whereas the not seeded Ti tubes fully occlude after 3-21days(51). 
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1.5 Tissue engineering  
 
“Tissue engineering is an interdisciplinary field that applies the principles of engineering and 
life sciences toward the development of biological substitutes that restore, maintain, or 
improve tissue function or a whole organ” Langer & Vacanti (1993)(52) 
 
“There is an inherent, virtuous logic to tissue engineering that sounds too good to be true. 
By my definition, tissue engineering is the persuasion of the body to heal itself, achieved by 
the delivery to the appropriate site of cells, biomolecules, and supporting structures.” 
Williams (2004)(53) 
 
1.5.1 Principle of tissue engineering 
The principle of tissue engineering is based on three important subjects: cells, scaffolds and 
signals (figure 8). All three parts are equally important and strongly connected to each other. 
The cells for instance, need to be autologous from the patient and need to be differentiated 
according to their further function. To create a three dimensional tissue, the cells need a 
structure to grow on - the scaffold. The scaffold elementarily affects the mechanical 
properties, the cell adhesion and growth. To keep the new tissue functional and alive, signals 
like growth factors but also mechanical stimulation is crucial. Without the right stimulation 
by chemical and mechanical signals the tissue formation does not fulfill the requirements 
and the cells might differentiate in the wrong direction. So there is no way just to focus on 
one part of the triad. To achieve an optimized implant performance, the right origin of cells, 
a sufficient biomaterial surface chemistry and signals like hemodynamics for endothelial cells 
(EC) must be considered.  
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Figure 8: The triad of tissue engineering is based on the compartments: cells, scaffold and 
signals. The cell source is characterized whether it is autologous and the differentiation of 
the cells. The Scaffold as base for cell growth can either be natural or synthetic. The signals 
addressed to stimulate the cell growth involve mechanical and chemical signals. There are 
a lot of possible parameters and each interacts with the others. Therefore, in tissue 
engineering all three compartments and their correlations have to be considered. 
 
1.5.2 Scaffolds 
The aim of tissue engineering is to implant newly grown tissue for replacement. For most 
issues a three dimensional structure is required. Scaffolds are used to form those complex 
structures. Scaffolds can be either natural or synthetic. The used scaffold is chosen by the 
requirements of the cells and the further function. The field of tissue engineering has 
become as wide as the field of used scaffolds. This overview will therefore focus on scaffolds 
in the field of cardiovascular tissue engineering and especially on the function for endothelial 
growth. By the important role of endothelial cells in the blood vessels, a limited attachment 
to the graft could lead to awful risks, starting by altered phenotype leading to EC activation, 
unexpected responses to hemodynamic forces, thrombosis and ultimately graft failure(28). 
Cells
- autologous
- differentiated
Signals
- mechanical
- chemical
Scaffold
- natural
- synthetic
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In nature, cells grow on extracellular matrix (ECM), so it is not surprising that a lot of 
scaffolds are based on ECM-protein. To ensure the extensive complexity of the ECM, an 
often used method is to decellularize native tissue for scaffold usage(28). Besides using the 
whole matrix, other common scaffolds are based on matrix components, like collagen, 
fibrinogen and elastin. A brief overview of used scaffolds is given in table 4. 
 
Table 4: Scaffolds in the field of tissue engineering. 
 Scaffold Description 
N
a
tu
ra
l 
sc
a
ff
o
ld
s 
Decellularized matrix Natural matrix structure and components, good cell 
adhesion, risk of immunoreaction 
Collagen Natural protein 
Fibrinogen Autologous gel formation, weak structure 
Elastin Natural protein 
Hyaluronan acide 
glycosaminoglycan  
Important in cell proliferation, migration and 
angiogenesis and wound repair 
Matrigel A mouse sarcoma derived ECM 
Silk fibroin Part of the silk made by silkworms 
Peptides Self-assembling peptides 
S
y
n
th
e
ti
c 
sc
a
ff
o
ld
s 
Poly(-caprolactone) (PCL) Degradable polymer 
Polyethylene glycol (PEG) Synthetic hydrophilic polymer, 
hydrogel formation, degradable 
Poly(lactic-co-glycolic 
acid) 
(PLGA) 
Common FDA approved material used in TE(28) 
Polyethylene 
terephthalate (Dacron ®) 
Synthetic material, increased calcification 
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Decellularized matrix 
Decellularized matrices are often used. Cells are removed by flushing and perfusion of donor 
tissue with detergents and buffers. By this procedure, the matrix and geometry of the tissue 
is preserved. Xenogeneic or allogeneic organs or tissues are used as source. 
The decellularized tissue is often used as a matrix substitute due to its natural source. The 
native fiber structure provides a good surface for EC adhesion, proliferation, differentiation 
and migration. The natural deposition of fibronectin supports the cell adhesion, and growth 
factors like FGF-2 and VEGF support the cell regeneration and differentiation. This makes 
decellularized vessels a suitable scaffold for vascular tissue engineering. The decellularization 
needs to be done carefully and entirely, because remaining cell parts may cause calcification 
and rapid immune reactions. Furthermore, the ECM might change their biomechanical 
properties due to the chemical and physical stress during decellularization(33). 
 
Collagen 
Collagen is one of the main ECM proteins with excellent cell-binding properties, outstanding 
tensile strength and incorporated growth factors like VEGF and FGF2. With its highly 
preserved tertiary protein structure it is very likely to be used as scaffold material in tissue 
engineering. There are different methods to use collagen. One is to use it as a membrane, 
for example made of equine/bovine pericardium(54), bovine tendon(55),(56), or porcine 
small intestinal submucosa (SIS) (33),(57). Another option is electrospinning into fibrous 
scaffolds for vascular grafting(58). Collagen hydrogels are commonly used. Already in 1986 
Weinberg-Bell, a pioneer in cardiovascular tissue engineering, used collagen gels including 
SMC and fibroblasts (FB) coated with EC(59). 
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Fibrinogen 
One common scaffold material is fibrinogen. It is mainly used in the cardiovascular field and 
the cartilage and skin tissue engineering. Fibrinogen is a 340 kDa plasma protein mainly 
involved in wound healing.  
 
 
 
 
Figure 9: During fibrin formation the N-termini of the α- and β-chains of the fibrinogen are 
cut by thrombin, followed by protofibrill formation and three dimensional fibrin gel 
formation. Reprinted from The Plasma Proteins 2
nd
 edition, Putnam, F. W. page 148 (1984), 
with permission from Elsevier. 
During wound healing, it spends a temporary matrix for cell invasion. It is built of two identic 
subunits each containing a D-Domain and three superhelical (coiled coil) alpha helices Aα, Bβ 
and γ (figure 9). The N-termini of those three chains are located in the E-domain. The D-
C-termini α-chain 
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domain is at the sides of the protein. By adding thrombin, the fibrinogen peptides A and B, 
of the two helices Aα and Bβ, are cut off which leads to a change in solubility. The soluble 
fibrinogen changes to the insoluble fibrin. Double chained protofibrills are formed, D-E-D 
interactions are formed, followed by the α-chain loosen from the central region. The 
protofibrills form three dimensional fibrin networks.  
Fibrinogen is very suitable for tissue engineering. First, it is a natural scaffold physiologically 
available in the body. Furthermore, the main compartments, like thrombin and fibrinogen, 
can be easily isolated from the patient’s blood and a completely autologous scaffold can be 
produced. The rejection by the body is therefore unlikely. Furthermore the ECM production 
is increased, unlike in collagen scaffolds. Also a placement of the cell during molding process 
is possible. Because of the fast polymerization, the cells are homogeneously distributed in 
the gel. Another advantage is the controllable degradation by protease-inhibitors, like 
aprotinin(60) or tranexamic acid (ε–aminocaproic acid, t-AMCA)(61). The mechanical 
weakness is a deficit of fibrin. Therefore, a combination with other scaffolds or a 
preconditioning with cells is recommended. For mechanical support, highly porous synthetic 
biodegradable scaffolds are very convenient(62). 
 
Elastin 
Elastin is one of the main proteins found in the extra cellular matrix. The precursor 
tropoelastin is synthesized by SMC, EC, FB and other cells. Its main role in the body is to 
provide the tissue with elasticity, but it is also involved in the modulation of cell behavior 
and promotion of tissue repair(63). 
The general structure of elastin is based on repeated motifs, such as VPGG, VPGVG, APGVG 
and VGVAPG.  
Mimicking those repeated motifs, artificial polypeptides were created, the so called elastin-
like polymers (ELP). Because of their natural inspired biomimetic material they are highly 
biocompatible and hemocompatible(64),(65). Elastin-like recombinamers are one special 
form of ELP created by the Bioforge group of Prof. José Carlos Rodríguez-Cabello, University 
Valladolid, Spain. The ELRs are a combination of newly developed and natural protein 
elements, thus the sequences are artificial and the genes must be designed and synthesized 
de novo(63). Therefore the ELRs can be positioned midways between natural and synthetic 
polymers with the advantage of a controllable scaffold combined with natural 
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properties(66). By using click chemistry(67), the gelformation is even possible under 
physiological conditions without cell harming as already proven by Salvani et al.(68). 
 
1.5.3 Signals 
Cells are highly influenced by their environment. Therefore, the microenvironment of the 
cells in culture needs to be defined carefully for tissue engineering. The tissue culture can be 
influenced by defined supplements, other cells and induced forces. Mainly, we distinguish 
between chemical signals and mechanical signals. 
 
Chemical signals 
Chemical signals can be distributed by the medium or by the surrounding cells. For cell 
culture, special culture medium is available, supplying the cells with the required nutrients 
and growth factors. Additionally the growth is triggered by the surrounding cells. If there are 
too few cells in culture and any contact fails, the cell culture dies. If instead the cell culture 
already grew over the entire surface the cells inhibit further proliferation. Furthermore, co-
culture systems with direct or indirect contact can be used to induce directed differentiation. 
 
Mechanical signals 
Mechanical signals can be addressed by scaffold stretching, for example during vessel 
dilatation. In vascular tissue engineering the stimulation by flow is a common and needed 
stimulation. The cells get stimulated by the pressure and the flow rate, addressed on the 
surface. This triggers the ECM production of SMC and stimulates endothelial cells, which 
orient themselves parallel to the blood flow. 
 
1.5.4 Cell types 
There are two different ways to achieve functional cells for tissue engineering. On the one 
hand, taking differentiated cells from the origin of interest or on the other hand taking stem 
cells and differentiate them into the cells of interest. Both methods have their advantages 
and disadvantages. Using cells from the organ which needs tissue-engineered constructs to 
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be replaced, the advantage is that the cells are already differentiated correctly and have the 
achieved functionality. However, thinking of a diseased person, there might not be healthy 
tissue available. Using stem cells might solve the problem of cell availability, but those cells 
have to be differentiated into the required cell type. Although a lot of research was put into 
differentiation of stem cells, still it is not completely understood. Another problem which 
occurs besides the cell availability is the required cell number. To reach the needed cell 
number of several millions you could either harvest the needed amount or increase the cell 
number in cell culture. Harvesting such a large number of cells is often a problem. Most 
researchers therefore increase the cell number by cell cultivation inside the laboratory. 
Cultivating and expanding cells over several weeks keeps the risk of dedifferentiation or 
transdifferentiation. Already at this stage, the supply of the right culture medium, including 
growth factors, is crucial. 
To form a complex tissue, also the involvement of different cells as supporting cell types and 
co-cultures should be considered. For example, in vascular tissue engineering smooth muscle 
cells (SMC) or pericytes as supporting cells are required to create a stable vasculature(28) as 
matrix for the endothelial cells. 
 
1.6 Endothelium 
The endothelium is a monolayer of endothelial cells (EC) lining the inner surface of about 
100,000 km of blood vessels in our body. The total number of 10
13
 endothelial cells is 
assumed, with a total weight of 1.5 kg. With a surface area of 4,000-7,000 m
2
 (69) they build 
the biggest secretory tissue with direct contact to blood(70). 
The endothelial cells build an epithelial monolayer, oriented parallel to the bloodstream. The 
cells are connected to each other by tight junctions, adhesion contacts and gap-junctions 
(figure 10). To the extra cellular matrix (ECM) of the basal membrane, the endothelial cells 
are connected by focal contacts(71).  
In 1973, for the first time, endothelial cells were isolated out of human vessels for cell 
culture treatment (72). Since then, a lot of research was done in the field of endothelial cell 
biology.  
The high interest into the endothelial cell biology is based on the important functions of the 
endothelial cells. As an interface between the circulating blood and the tissue, highly 
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important barrier functions are obvious, like transportation of cells and nutrients. They 
control the nutrient diffusion and the macromolecular plasma molecules passing to the 
subendothelial tissue by the tight junctions. Also the control of the vasomotor tone is 
regulated by the endothelial cells through vasodilators like nitric oxide (NO) and prostacyclin 
and vasoconstriction molecules like endothelin and angiotensin converting enzyme (ACE) 
which are produced by the endothelium(71) ,(73). 
Beside the vasoconstriction and vasodilation molecules, there are also ECM molecules 
secreted by the endothelium. 
 
 
 
Figure 10: Pattern of endothelial cells showing tight junction, adhesion contacts, gap 
junction, actin filaments, Weibel-Palade bodies with vWF, eNOS and mitochondria. 
 
ECs synthesize matrix molecules like collagen IV, proteoglycans and laminin. Furthermore, 
growth stimulating and inhibiting factors are synthesized, like the platelet derived growth 
factor (PDGF), the colony stimulating factor (CSF) and the fibroblast growth factor (FGF). 
Inhibiting factors like Heparin and TGF-β (transforming growth factor-β) are known to be 
secreted by endothelial cells as well. Furthermore the interleukins IL-1, IL-6 and IL-8 are 
Tight junction 
Adhesion contacts 
Gap junction 
Weibel-Palade 
bodies with vWF 
Mitochondria 
Actin filaments 
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produced, like adhesion molecules and histocompatible antigens to regulate 
inflammation(71),(73). 
Inhibition of thrombocyte adhesion is of high interest concerning diseases. ECs produce 
anticoagulative and antithrombotic molecules. Namely: prostacyclin, thrombomodulin, 
plasminogenactivator and heparin-like molecules. By secretion of prostacyclin the 
thrombocyte aggregation is inhibited(71) ,(73). 
Endothelial cells do not only inhibit the thrombocyte adhesion, they also produce 
thrombocyte adhesion supporting molecules. For example, the thrombocyte adhesion is 
supported by von Willebrand factor (vWF) secretion, which can adhere if the endothelial 
layer is damaged. The vWF triggers the adhesion of thrombocytes by containing receptors 
for thrombocyte adhesion. Another pro-thrombotic factor is the plasminogen-activator-
inhibitor, which can be secreted by the ECs as well. At injuries, it inhibits the degradation of 
fibrin by plasminogen activators(71) ,(73). A summary of endothelial cell function is given in 
table 5. 
In response to their microenvironment, endothelial cells change reversibly(74). Angiogenic 
potential, molecular permeability, leukocyte transmigration, hemostasis, vascular tone, 
humidification, thermoregulation and even immune tolerance can vary extremely between 
ECs from different sources (e.g. small versus large diameter vessels)(28).  
 
“An important feature of the endothelium is that its properties vary between different sites of 
the vasculature and from one moment in time to the next” Aird (2005)(2) 
 
This for example leads to completely different cell expression of endothelial cell activation. 
Activated ECs express procoagulatant, proadhesive and vasoconstricting properties, 
compared to the anticoagulant, antiadhesive and vasodilatory phenotype in quiet cells(2). 
These multivalent cell properties also affect the research of cell culture. Once taken from the 
native environment, the cells change in phenotype during cell culture. This has to be 
considered and additional in vivo experiments are needed to confirm the in vitro results. 
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Table 5: Function of endothelial cells 
Physiological processes Pathological processes 
 Barrier function  Leukocyte adhesion 
 Trafficking of cells and nutrients  Antithrombotic properties 
 Control of vasomotor tone  Anticoagulative properties 
 Angiogenesis  Inflammation regulation 
  Hemostasis initiation 
 
1.6.1 Endothelial cell origin 
The endothelial cells are differentiated from endothelial progenitor cells (EPC). During 
embryogenesis the blastocyst is formed. The contained pluripotent embryonic stem cells 
develop to mesodermal stem cells. Those are able to develop into endodermal stem cells, 
ectodermal stem cells or hemangioblasts. The hemangioblasts can develop to hematopoietic 
stem cells or into the early endothelial progenitor cells. The early EPCs differentiate further 
to late EPCs and finally to the endothelial cells. As a part of the bone marrow, the 
hemangioblasts produce EPCs and deliver them to the blood stream. 
 
1.6.2 Endothelial cell characterization 
For cell characterization different criteria can be considered by morphology or expression of 
EC specific proteins. By light microscopy, the morphology of the endothelial cells can be 
characterized and is known in cell culture to show a coble stone like structure. In native 
vessels the cells are orientated to the stream of the blood flow. The Weibel-Palade-bodies 
are also seen under the light microscope. Those 0.1×2 µm small cell organelles are placed in 
the cytoplasm of endothelial cells and store the vWF(75). For more precise cell 
characterization, cellular markers as vWF, CD31, KDR (VEGFR-2) and eNOS are appropriate 
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markers. Endothelial cell genes may be classified by their specificity and whether they are 
constitutively or inducibly expressed(74). 
 
1.6.2.1 CD31 (PECAM-1, platelet endothelial cell adhesion molecule-1) 
CD31 was first identified in 1980(76). It is a 130 kDa transmembrane glycoprotein and, as a 
constitutively expressed marker, specifically expressed on endothelial cells. As an adhesion 
supporter, CD31 is located mostly at cell-cell and cell-matrix boundaries. By this, CD31 is the 
base for the diffusion barrier function of the EC(77). CD31 is also involved in inflammatory by 
transporting leucocytes and neutrophiles through the endothelium.  
 
1.6.2.2 vWF 
The von Willebrand factor (vWF) is a glycoprotein located in the Weibel-Palade bodies (WPB) 
of endothelial cells. vWF is specific for endothelial cells and is inducible expressed. 
Transporting the blood clotting factor VIII, it has an important role during the blood clotting 
cascade. Through an injury of the blood vessel wall, vWF is exposed from the WPB to the 
cytoplasm and thrombocytes can bind to vWF by their vWF-receptor and lead to blood 
clotting. The vWF expression is programmed by the tissue microenvironment and is not a 
fixed property of the endothelial cells(74). The release of vWF is increased by fibrin, 
histamine, vasopressin and shear stress(78). 
 
1.6.2.3 KDR /VEGFR-2 
The kinase insert domain receptor (KDR), also known as vascular endothelial growth factor 
receptor 2 (VEGFR-2), is a growth factor of the VEGF receptor family. It mediates the growth 
factors VEGF-A, -C, -D and -E. Those signals support the cell preservation, proliferation, 
starting signal of angiogenesis, growth of focal contacts, influence on vascular permeability, 
stimulation of NO production and endothelial migration(79),(80). The KDR expression is 
regulated by the oxygen content of the surrounding tissue and by the cell density (79),(81). 
 
 47 
 
1.6.2.4 eNOS 
The endothelial nitric oxide synthase (eNOS) is a specific, inducible marker for endothelial 
cells. Endothelial cells are one of a few cell lines able to synthesize nitric oxide (NO). NO is an 
intra-cellular messenger with several functions like vasodilatation, thrombozyte aggregation 
inhibition, LDL-oxidation and superoxidradical production. This leads to an antithrombotic, 
antikoagulative and antimigrative impact. Furthermore, the blood pressure is reduced. The 
eNOS expression is triggered by the growth factor VEGF-A, hypoxia and shear stress. At static 
conditions, the mRNA expression is reduced and so is the protein level of eNOS(70). 
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2 Aims of this study 
Major causes of stent failure are due to strut cracking and/or intima hyperplasia. Those 
problems were addressed by new stent structure design and drug eluting stents. The 
patency increased, but still restenosis occur and requires improvement. Therefore I 
hypothesize that a viable stent structure based on a tissue covered stent will prevent 
thrombocyte adhesion and hyperplasia. 
 
1.  
Figure 11: The concept of the BioStent(82) is based on a self-expandable stent structure 
covered in a autologous tissue, lined with endothelial cells. By coverage, total plaque 
exclusion is addressed. The endothelial cell lining expect a hemocompatible surface. 
 
The aim of this study is to construct a tissue-covered endothelialized stent, the BioStent 
(figure 11). Tissue engineering gives the chance to create new and healthy tissue which can 
replace the native one where it is damaged. By combining stents with tissue engineering, the 
stent is surrounded by autologous tissue and therefore on the one hand the foreign object 
reaction is avoided and on the other hand the damaged tissue is replaced by a new healthy 
tissue layer. The most important advantage is the endothelial layer with its known and 
important role of anti-thrombotic and anti-coagulative function.  
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Open questions to be addressed in this thesis are: 
I. What is the optimal cell- source for endothelialization of the BioStent? 
There are two common sources for endothelialization: first, adult endothelial cells 
from the blood vessels and second, endothelial progenitor cells out of the blood. 
Both cell types were evaluated as stent coating. Additionally endothelial cells were 
analyzed in regard to trans- or dedifferentiation in culture.  
 
II. What is the ideal stent design for the tissue covered stent?  
A lot of stents show a long foreshortening during crimping. With a tissue covered 
stent this would lead to damage of the tissue. A low tissue deformation and at the 
same time a strong radial force and low bending stiffness is needed. In this thesis 
different stent structures are tested mechanically and for coating. The ability for 
coating is evaluated by crimping and releasing tests. 
 
III. Which biomaterial is the best scaffold for the BioStent?  
In this thesis the two hydrogels fibrin and elastin-like recombinamers were tested as 
scaffold because of their biocompatibility, easy molding ability and elasticity. For the 
BioStent the scaffolds have to prove the ability for endothelialization and the 
endothelial cells have to resist flow conditions. This will be tested by molding and 
bioreactor conditioning with additionally crimping and release tests. The gels need to 
prove a thin coverage and no damage during crimping. 
 
IV. Proof of function in vitro: can the BioStent prevent thrombocyte-adhesion? 
The best results of question I-III will be evaluated in vitro. The hemocompatibility is 
tested in a Chandler loop system with human blood. The in vitro tests need to prove 
a healthy tissue formation, a thin coverage and prevention of thrombocyte adhesion. 
 
V. Proof of function in vivo: can the BioStent withstand the blood flow and keep 
patient?  
As final proof of concept the implantation in healthy sheep is addressed. After three 
months of implantation a patent and still endothelialized stent without thrombosis is 
expected. 
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3 Material and methods 
3.1 Evaluation of sources of endothelial cells 
There are two common sources for endothelialization: first, adult endothelial cells from the 
blood vessels and second, endothelial progenitor cells out of the blood. Both cell types were 
evaluated as stent coating (endothelialization and conditioning). Another common problem 
is the trans- or dedifferentiation of cells in culture over time. A decision has to be made until 
which passage the cells are still usable.  
 
Figure 12: Process line for cell evaluation. Top down the steps for cell culture, molding and 
conditioning and analysis methods are shown. SMC = smooth muscle cells; FB = fibroblast; 
EC = endothelial cells; EPC = endothelial progenitor cells; FACS = fluorescence activated cell 
sorting; qPCR= quantitative real time polymerase chain reaction.  
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In figure 12 the experimental workflow is shown. For evaluation endothelial cells from 
umbilical cord and endothelial progenitor cells out of blood were isolated and proliferated in 
cell culture. Endothelial cells from carotid were cultivated in two different media and grown 
colonies were counted to optimize the cultivation method. Stents for EC and EPC coating 
were prepared by molding with fibrinogen and smooth muscle cell / fibroblasts. In a first 
step, stents were endothelialized with EC and cultivated for 4, 6 and 8 days. In further 
experiments 7 days for cultivation were used. In comparisson EPC were seeded on stents 
and cultivated for 7 days as well. For visualization the EPC were stained with DiI-Ac-LDL prior 
seeding and analyzed after conditioning. Both EC and EPC covered stents were analyzed by 
scanning electron microscopy.  
For further analysis over several passages only EC were used. It was not possible to passage 
the EPC. The EC were analyzed over 10 passages on transcrimptional level (qPCR) and 
translational level (FACS-Analysis). All protocols of the single steps are described below. 
 
3.1.1 Cell culture 
All cells were isolated out of fresh tissue samples. The smooth muscle cells (SMC) and 
fibroblasts (FB) were isolated out of human umbilical cord arteries. The endothelial cells (EC) 
were isolated out of human umbilical cord veins (HUVEC). The human endothelial progenitor 
cells were isolated out of buffy coats. All cells were cultivated under standard conditions in 
humidified bioreactors at 37 °C and 5 % CO2.  
 
3.1.1.1 Primary cell culture  
All cells were isolated out of fresh tissue samples and cultivated in tissue culture flask at 
37 °C in a 95 % humidified incubator (Binder) supported by 5 % CO2. For in vitro experiments 
cells from humans and sheep were use. Sheep cells were used as preparation for the animal 
trials within sheep. To prove visibility for human application also tests on human cells were 
done. The used cell type is always mentioned at the beginning of the chapters. 
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3.1.1.2 Cell isolation out of human blood 
The used endothelial progenitor cells (EPC) were isolated out of human blood. For each 
experiment buffy coats of 16 donors were pooled. Buffy coats are blood samples without 
blood plasma. The blood was extracted into 50 ml syringes (Braun, 8728810F) using a 20 G 
needle and gently mixed with 5 ml Citrat Dextran (2.5 ml Dextran 6 % Sigma , D1037 + 2.5 ml 
trisodium citrate 3.13 %, Eifelfango) to avoid blood clotting. The syringes were kept still until 
two phases were defined, approximately 45 min. At the bottom the red blood cells were 
defined and above the mononuclear cells inside the serum. The upper phase was removed 
carefully and placed on the Ficoll 1.077 g/ml (Biochrom AG, L6115) for defined density. 50 ml 
reaction tubes were prefilled with 17.5 ml Ficoll and accumulated to 50 ml with the serum. 
The reaction tubes were centrifuged for about 20 min at 400 x g using no break. Because of 
their higher density, the erythrocytes and granulocytes went through the Ficoll and remain 
on the bottom. The lighter monocytes remain above the Ficoll in the so called Interphase. 
The serum remaining on the top was removed. The buffy coat interphase was removed by a 
10 ml pipet and placed in a fresh reaction tube, filled up to 50 ml with PBS and centrifuged 
for 15 min at 300 g. Two washing steps were done with PBS by centrifugation at 200 x g for 
15 min. The cell density was measured using the Neubauer chamber. The cells were re-
suspended in cell culture medium (Promocell, C22221) and placed in coated cell culture 
flask. The cell culture flask were coated with fibronectin (Tebu-Bio, Cat.No.: 2003) 10 µg/ml. 
In culture, the EPCs adhered to the fibronectin and nonattached cells were removed during 
the medium change. The cells were used 3 days after isolation and are called early 
outgrowth EPC. 
 
3.1.1.3 Endothelial cell isolation out of human umbilical cord 
The used cells were harvested from human umbilical cord (UC). The UCs were stored in 
transport buffer (1 %) at 4 °C until isolation. The UC vein was cannulated and flushed by PBS 
(phosphate buffered saline, Dulbecco’s PBS, PAA, H15-002) under sterile conditions. For 
endothelial cell harvesting preheated collagenase (0.2 %, TypII, Gibco 17101-015) was 
inserted and incubated for 45 min at 37 °C. Thereafter the UC vein was rinsed with PBS and 
the eluate was centrifuged at 500 x g for 5 min. The supernatant was rejected and the cells 
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resuspended in endothelial growth medium (EBM-2, Lonza, CC-3156). The cells were 
cultured in gelatine pre-coated cell culture flasks. 
 
3.1.1.4 Smooth muscle cell / fibroblast isolation (SMC/FB) out of human umbilical cord 
After endothelial cell isolation the two arteries of the UC were prepared and cleared from 
the Wharton's jelly. Small rings of the vessels were cut and placed in a cell culture flask. The 
rings were provided with cell culture medium (DMEM, Gibco, 21885-025). After a few days, 
SMC/FB grow out of the rings. 
 
3.1.1.5 Endothelial cell isolation out of ovine carotid 
Endothelial cells were harvested from ovine carotid artery. The carotid arteries were stored 
in transport buffer (1 %) at 4 °C until isolation. The artery was cannulated and flushed by PBS 
(phosphate buffered saline, Dulbecco’s PBS, PAA, H15-002) under sterile conditions. For 
endothelial cell harvesting preheated collagenase (0.2 %, TypII, Gibco 17101-015) was 
inserted and incubated for 45 min at 37 °C. Thereafter the artery was rinsed with PBS and 
the eluate was centrifuged at 500 x g for 5 min. The supernatant was rejected and the cells 
resuspended in endothelial growth medium (PAA, U15-011 + U05-012). The cells were 
cultured in Gelatine pre-coated cell culture flasks. 
 
3.1.1.6 Smooth muscle cell / fibroblast isolation (SMC/FB) isolation out of ovine carotid 
After endothelial cell isolation the artery was cleared from the adventitia. The artery was cut 
in small rings which were placed in a cell culture flask. Those rings were provided with cell 
culture medium (DMEM, Gibco, 21885-025). After a few days, SMC/FB grow out of the rings. 
 
3.1.1.7 Passaging of cells 
Detachment of the cells was performed by incubation for 5 min with trypsin 
(0.25 %trypsin/0.02 %EDTA, Gibco). After detachment the reaction was stopped by adding 
Material and methods 
54 
culture medium. The cell suspension was divided up 1:3 on new culture flasks. For 
endothelial cells the flasks were coated with 2 % Gelatine formerly. 
 
3.1.1.8 Cryo conservation 
For cell storing the cells were frozen and stored in a nitrogen tank until use. The cells were 
detached by trypsin. The reaction was stopped with cell culture medium. Cell suspension 
was centrifuged at 500 x g for 5 min. The supernatant was rejected and the cells 
resuspended in cell culture medium with a cell density of 2-10 million cells per ml. The same 
amount of freezing medium (60 % cell culture medium, 20 % FCS, PAA, A15-151, 20 % DMSO, 
Sigma, D2650) was added. The cell suspension was stored in cryo tubes (Greiner, 8070176). 
In a first step the tubes were stored in Isopropyl alcohol for at least 12 h at -80 °C. 
Afterwards they were stored in liquid nitrogen until use.  
For cell defreeze the tubes were warmed in a 37 °C water bath. The cell suspension was 
added to 10 ml cell culture medium and centrifuged (500 g, 5 min). The supernatant was 
rejected and the cells resuspended in fresh culture medium and placed in new cell culture 
flasks. 
 
3.1.1.9 Cell characterization 
The phenotype was verified by immunohistochemistry staining against von Willebrand factor 
(vWF) to proof endothelial cells and against alpha smooth muscle actin (αSMA) to prove 
smooth muscle cells. For staining a sample of the cells was taken during the last splitting 
process and cultured in a pre-coated 24-well plate. The cell growth was proved by 
microscopy. After a good cell attachment and growth was achieved, the cells were fixed by 
methanol for 10 min at -20 °C. For blocking 5 % BSA was used. As primary antibody either 
vWF or αSMA was used and incubated for 30 min. After washing with 0.1 % Triton-PBS the 
second antibody Alexa Fluor 488 (green) or 594 (red) was added for another 30min. Nuclei 
were stained with DAPI. 
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3.1.2 Staining of endothelial progenitor cells (EPC) with DiI-Ac-LDL 
Prior to cell seeding the EPC were stained with DiI-Ac-LDL (Cell Systems, CS-D0120) for 
further detection. DiI-Ac-LDL is an acetylated low density lipoprotein coupled to the 
fluorescence dye 1,1’dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine (Dil). It is specific for 
endothelial cells. For staining, the cell culture flasks were washed with PBS first. Then the 
staining solution of 2 ml cell culture medium and 100 µl DiI-Ac-LDL was added and 
distributed on the bottom. After four hours of incubation the dye was removed and fresh 
cell culture medium added for further cultivation. The staining was checked under the 
microscope at 514 nm excitation and 550 nm absorption. 
 
3.1.3 Molding with SMC/FB and fibrin-gel 
For the coverage autoclaved stents were embedded in fibrin-gel using a molding system 
(figure 13). The stent was placed inside a silicon tube (ID 8.0 mm) and connected on both 
sides with ¼ inch connectors. To leave the lumen open, an inner cylinder (OD 5.5 mm) was 
inserted. The two solutions A and B (table 12) were injected by a two chamber syringe 
system (Baxter). The solutions were mixed inside the mold and polymerized within a few 
seconds. The included SMCs/FBs were encapsulated inside the gel. A concentration of 
12·10
6 
cells/ml was used in a fibrin-gel with a final concentration of 5 mg/ml. The inner 
cylinder was removed after 45 min and the stent immediately placed into bioreactor 
medium. 
 
3.1.4 Endothelialization 
For endothelialization a rotational system was used (figure 14). The stent placed in a tube 
was clamped on both sides. The medium surrounding the stent was removed and the 
endothelial cell suspension was injected. A total volume of 5 ml (4·10
6 
EC/ml) was injected. 
To allow a homogeneous lining the stent was fixed to a rotating rod. A stepwise rotation was 
performed for about 6 h. The stents were rotated by 120° in each step. They rested for 
about 200 sec between the rotation steps to let the cells adhere. Afterwards the cell 
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suspension was removed and cell concentration was measured using the cell counter system 
CASY (CASY, model TT).  
 
 
 
Figure 13: Molding system including a silicone tube as outer cylinder, a metal rood as inner 
cylinder and connectors on both sides for further connection to the bioreactor. The stent 
sticks between the two connectors. A double syringe is used for simultaneous injection of 
the fibrinogen in the one chamber and cells, thrombin and CaCl2 in the other chamber. The 
polymerization starts by contact and fibrin gel is formed. The endothelial lining is 
performed in a second step. A cross section which illustrates the coating of the stent is 
shown on the right hand side. SMC = smooth muscle cells; FB = fibroblasts; EC = 
endothelial cells. 
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Figure 14: Rotational endothelialization. The stent was rotated stepwise for 20 sec with 
1 rpm and rested for 200 sec. In total, 6 hours of endothelialization were performed to 
allow the cell suspension in the lumen to cover the whole stent. 
 
3.1.5 Bioreactor cultivation 
After molding the stent, the tissue formation was supported by dynamic cultivation. 
Therefor the stent within the molding tube was connected to a circular silicon tubing system 
(figure 15). For medium supply a reservoir was attached to the system. By a roller pump a 
pulsatile flow was forced through the stent. The flow rate was adjusted to 50 ml/min at the 
beginning and raised up to 100 ml at day two. Using a pressure clamp, the pressure was 
adjusted to 120 (systole) to 80 (diastole) mmHg at day two.  
The cells were provided by bioreactor medium based on cell culture medium. To inhibit the 
fibrinogen degradation 1.6 ml/l cyclocapron (Pfizer) were added. Furthermore, ascorbic acid 
(0.29 mg/ml medium) was added to support the extracellular matrix production. The 
cultivation was performed inside an incubator at 37 °C and 5 % CO2. The silicon tubes are gas 
permeable to guarantee gas exchange. Fibrin covered stents were preconditioned before 
endothelialization for two weeks. Elastin covered stents were endothelialized without 
preconditioning. 
After the endothelialization the flow was set to 50 ml/min and increased 10 ml/min each day 
up to 120 ml/min for at least one week. 
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Figure 15: Bioreactor system: left photography of the bioreactor without the pump, right 
schematic of the bioreactor system. For cultivation the bioreactor is put inside an 
incubator at 37 °C and 5 % CO2. 
 
The shear stress in the bioreactor system was calculated as shown below. At a maximal flow 
rate of 110 ml/min the shear stress was about 0.16 Pa. 
 
The shear stress () can be correlated to the shear rate () and the dynamic velocity (µ) by 
    ∙ 
 
                                          (eq 1) 
shear stress 
 
The shear rate was calculated by(83) 
 
 
8
2
                                           (eq 2) 
shear rate 
 
where  is the fluid velocity and 2  the inner diameter of the tube. The fluid velocity () can 
be calculated by the volumetric flow rate   and the cross section area of the tube (At) as 
follows. 
 
 


                                          (eq. 3) 
fluid velocity 
Where the cross section of the tube (At) is calculated by  
   
 
                                         (eq. 4) 
cross section area of tube 
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Substituting the two equations above into the shear rate equation results in 
 
 
8(


)
2
 
 
which can be simplified to 
 
 
4

                                          (eq. 5) 
simplified shear rate 
 , as the volumetric flow rate, is defined as the flow of volume of fluid (V) through a surface 
per unit time (t). 
 
 


                                          (eq. 6) 
folume flow rate 
In the bioreactor system a maximal flow rate of 110 ml/min (1.83 ∙ 10  m3/s) was adjusted. 
The flow rate and the radius of the inner tube diameter r=0.00275 m can be inserted into 
the shear rate equation(eq 2) 
 
4


4 ∙ 1.83 ∙ 10  m
(0.00275m)
 116.5 s& 
 
The shear stress is correlated to the fluid viscosity. For the experiments cell culture medium 
was used which has a viscosity like water, of 1.4∙ 10 '( ∙ ). Integrating the shear rate and 
the blood viscosity into the shear stress equation, results in a shear stress of about 0.16 Pa. 
   ∙ 
  116.5 s& ∙ 1.4 ∙ 10Pa ∙ s  0.16 Pa 
 
3.1.6 Scanning electron microscopy (SEM) 
The surface of the stents was analyzed by scanning electron microscopy. For preparation the 
samples were fixed in 2 % glutaraldehyde in 0.1 Sorenson’s buffer (pH 7.4) for at least one 
day. After fixation the samples were dried using an increasing acetone line and final critical-
point drying (E-300 Critical Pont Dryer; polaron Equipment Ltd., Watford, UK). A thin gold 
coating was applied (Balzers SCD-030; BAL-TEC AG, Balzers, Liechtenstein). For imaging the 
Philips XL-30 ESEM FE ( Philips, Eindhoven, The Netherlands) was used.  
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3.1.7 FACS-Analysis 
Fluorescence activated cell sorting (FACS) is a laser based technology used for 
characterization of biologic samples by using specific fluorescent marked antibodies. The 
cells were separated by a very thin nozzle and characterized using a defined monochromatic 
laser. The distribution of the reflected light was measured by two sensors the forward 
scatter channel (FSC) and the sideward scatter channel (SSC). The FSC gives an impression of 
the size and the SSC on the granularity of the cells. The cells were stained against CD31, KDR 
and eNOS (R&D Systems GmbH). The stepwise protocol is in the appendix. 
The analysis was performed on the BD FACSCalibur 
TM
 (BD Biosciences, Heidelberg, 
Germany) using the CellQuest Pro software (BD, Bioscience). The measurement was started 
by defining the gate. In this step a known population of cells was analyzed and the 
population was defined by the FSC and the SSC excluding the debris and other populations. 
Once the gate was defined the samples were measured and the amount of the stained 
protein was correlated to the fluorescence signal. For negative control nonspecific staining 
was used (Isocontrol). 
 
3.1.8 Quantitative real time PCR 
Polymerase chain reaction (PCR) is a method to create numerous duplications of a specific 
DNA sequence. With the quantitative real time PCR (qPCR) also the quantity can be detected 
after each duplication, using a fluorescence signal. In this case SYBR® Green, an intercalating 
dye binding to the dsDNA, was used. Bound to the dsDNA the SYBR® Green fluorescence is 
increased. By measuring the fluorescence signal after each cycle (duplication) the DNA 
content can be detected in real time. 
Isolated mRNAs from the tissue samples were used to quantify the protein formation for 
specific proteins of interest, in this case CD31, vWF, eNOs and KDR.  
 
The mRNA is the link between the conserved information on the DNA and the expression in 
form of proteins (figure 16). By transcription of the DNA, RNA is produced and available for 
translation. The RNA already spliced and without introns is called mRNA . By translation the 
mRNA, amino acid sequences are assembled which form the protein. In each cell different 
proteins are requested and only needed ones are produced, so is the corresponding mRNA. 
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Therefore a direct correlation between the amount of mRNA and protein can be seen. Also 
other influences such as mRNA and protein stability should be discovered. 
 
 
 
 
 
Figure 16: Protein mRNA correlation. The protein information is stored in the DNA. By 
transcription, RNA is produced. The splicing process cuts the introns off and mRNA 
accurse. The mRNA can be translated to long amino acid strings which form proteins. 
Based on the amount of mRNA produced, a correlation to the protein production can be 
made. 
 
Starting the detection in a first step the mRNA has to be isolated out of the sample (chapter 
3.1.8.2) and has to be translated to complementary DNA (cDNA) (chapter 3.1.8.4). cDNA is a 
DNA without introns and serves as template for the PCR reaction. The qPCR was performed 
in a real time PCR cycler (StepOnePlus™, Applied Biosystem, Darmstadt, Germany) which 
allows local and precise temperature changes. Furthermore a fluorescence measurement 
unit is integrated. Starting with a temperature of 95 °C, the hot start polymerase was 
activated. By lower temperature the polymerase is inhibited by antibodies bound to the 
catalytic center to avoid nonspecific binding. Thereafter three-step-PCR-reaction was 
performed in cyclic repetition consisting of dissociation (dsDNA detached into ssDNA), 
annealing (primer attaching) and elongation (building new dsDNA) (figure 17). The 
measurement of the produced double stranded DNA (dsDNA) was performed by the 
fluorescence signal of the intercalating SYBR® Green. To detect specific mRNA, fitting 
primers were designed before starting the PCR. 
•DNA
transcription
•RNA
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•mRNA
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acid
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Figure 17: qPCR cycle consisting of dissociation (dsDNA detached into ssDNA), annealing 
(primer attaching) and elongation (building new dsDNA). During elongation the SYBR-
Green intercalate in the dsDNA, resulting in a fluorescence signal. The fluorescence signal 
can be measured and correlated to the amount of dsDNA. (dsDNA = double stranded DNA; 
ssDNA = single stranded). 
 
3.1.8.1 Primer design 
Primers are short nucleotide sequences which allow the attachment of the polymerase 
during PCR. The polymerase can only bind to a free 3’-end. Knowing that each DNA strand 
consists out of two complementary single strands, two primers need to be designed for each 
locus of interest. For best performance the following rules must be addressed. 
 
Rules for primer design 
- Primer length: The ideal primer has a length of 18 oligonucleotides but is at least in 
the range of 16-28. Larger primers produce more likely secondary structures which 
cannot bind to the DNA, shorter primers are less specific. 
 
- G/C content: There are four different bases: adenine (A), cytosine (C), guanine (G) 
and thymine (T). Adenine always binds to thymine and guanine to cytosine. The 
binding of A/T is a double binding whereas the C/G binding is threefold (figure 18). 
This leads to a higher dissociation temperature called melting temperature (Tm). The 
ideal melting temperature is between 52 and 63 °C. Tm is the temperature when the 
Start 
95°C
annealing 
60°C 
elongation 
60°C
dissociatio
n 95°C SYBR®-Green 
signal 
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double stranded DNA dissociates and can be calculated by summering the adenosine 
and thymidine basis multiplied by 2 plus the sum of cytosine and guanine times 4 
according to the Wallace rule(84). 
 
,-  . °0 ∙ (1 + ,) + 3 °0 ∙ (0 + 4) 
 
- Base repetition: The repetition of the same base should be avoided because it leads 
to increased secondary structure building. 
 
- Complementary palendroms should also be avoided to not increase the hairpin 
building. 
 
- At the 5’ end should be an increased density of C/G bindings 
 
- Being aware that the cDNA does not contains introns, the primer should therefore 
not bind to those.  
 
 
 
 
 
         Thymin Adenin            Cytosin     Guanin 
Figure 18: The nucleotide-binding between Adenin and Thymin consists of two hydrogen 
bonds and between Cytosin and Guanin consists of three hydrogen bonds. 
 
According to those rules the following primers were designed (table 6). 
Material and methods 
64 
 
Table 6: List of used Primer 
Primer Sequenz C/G content [%] Tm [°C] Annealing 
Temperature [°C] 
CD 31 (fwd) GCAGAGTACCAGGTGTTGGT 55 62 63 
CD 31 (rev) GAACAGTTGACCCTCACGAT 50 60 63 
KDR (fwd) CGGATAAGAACGTGGTTAAA  45 58 60 
KDR (ref) CGAGCATCTCCTTTTCTGAC  50 60 60 
eNOS (fwd) CGCTTCCTGTTTCTTAGTCG 50 60 60 
eNOS (rev) GGCACAGTCCCTTATGGTAA 50 60 60 
vWF (fwd) AACGTGCCAGAACTATGACC  50 60 60 
vWF (rev) CCACACATCTGTTCTCATGC 50 60 60 
Β-aktin (fwd) ATCCTGACCCTGAAGTACCC 55 62 60 
Β-aktin (rev) CACGCAGCTCATTGTAGAAG 50 60 60 
 
3.1.8.2 RNA Isolation for cell culture samples 
For RNA isolation of cells out of cell culture flask the cells were detached with trypsin and 
centrifuged at 500 x g for 5 min. The supernatant was wasted and the pellet lysed with RLT 
Buffer Plus (Quiagen) and stored at -80 °C until use. The RNA isolation was performed using 
the RNeasy Mini Kit (Qiagen, Hilden, Germany) following the manufacturers protocol. 
Afterwards the quantity of the RNA was measured using the NanoDrop spectrophotometer 
(Thermo Scientific, Schwerte, Germany). The stepwise protocol is added in the appendix.  
 
3.1.8.3 RNA Isolation for tissue samples 
The tissue samples of the stents were stored in RNA later at -80 °C until RNA isolation. For 
RNA isolation the RNeasy Micro Kit (Qiagen, Hilden, Germany) was used following the 
manufacturers protocol. Afterwards the quantity of the RNA was measured using the 
NanoDrop spectrophotometer (Thermo Scientific, Schwerte, Germany). The stepwise 
protocol is added in the appendix. 
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3.1.8.4 cDNA Production 
The cDNA synthesis was performed according to the manufacturer’s protocol of 
Super  Script ® VILO 
TM
 cDNA Synthesis Kit (Invitrogen, Darmstadt, Germany). The 
temperature protocol was performed in a thermo cycler (Eppendorf, Thermomixer 
compact). For storage the synthesized cDNA was frozen at -20 °C until use. 
 
Protocol for cDNA synthesis with SuperScript® VILO 
TM
 
1. For a single reaction add:  
I. 4 µl of 5x VILO
TM
 reaction mix 
II. 2 µl of 10x SuperScript® enzyme mix   
III. 100 ng of  RNA template   
IV. Adjust to a total reaction volume of 20 µl with RNAse free DEPC-
treated water.  
2. Mix 
3. Incubate at 25 °C for 10 min  
4. Incubate at 42 °C for 60 min 
5. Incubate at 85 °C for 5 min to stop the reaction 
6. Dilute with RNAse free water 1:5  
 
3.1.8.5 qPCR setup 
The PCR is a very sensitive measurement and therefore susceptible for pipetting mistakes. 
Therefore, two master mixes were prepared to minimize pipetting variations. After pipetting 
the master mixes were placed in a PCR plate (Micro AMP Fast Optical 96-well Reaction Plate, 
Invitrogen, 4346906) and centrifuged for mixing. The PCR was run in a real-time PCR cycler 
(StepOnePlus ™, Applied Biosystem, Darmstadt, Germany).  
 
Protocol for qPCR pipetting setup 
The stored primers were defrozen and diluted 1:10 with RNA-free-water with a final 
concentration of 10 mM.  
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Table 7: PCR setup components for one sample 
Chemical Volume 
POWER SYBR® GREEN (2x)   8 µl 
Primer forward & reverse (10µM) 3 µl 
RNAse free MilliQ 4 µl 
cDNA template (dilute stock again 1:5)   1 µl 
Total reaction volume   16 µl 
  
The setup was split in the primer master mix and the template master mix shown in the 
tables below. 
 
Table 8: Primer master mix 
P
ri
m
e
r 
 
m
a
st
e
r 
m
ix
  
Chemical Volume 
POWER SYBR® GREEN (2x)   4 µl 
Primer forward & reverse (10µM) 3 µl 
RNase free MilliQ 1 µl 
Total reaction volume   8 µl 
 
Table 9: Template master mix 
T
e
m
p
la
te
  
m
a
st
e
r 
m
ix
 
Chemical volume 
POWER SYBR® GREEN (2x)   4 µl 
cDNA template (dilute stock again 1:5)   1 µl 
RNase free MilliQ 3 µl 
Total reaction volume   8 µl 
 
Additionally, for each setup and primer a no template control (NTC) was made. The NTC 
contained RNase free water instead of primer. If amplification is detected in this sample a 
primer dimer must have been produced which influences the results. 
Furthermore, after each setup a melting curve was measured. By increasing the temperature 
stepwise and simultaneously fluorescence measurement primer dimers can be detected. 
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Each DNA sequence has a specific melting point Tm, reaching this point the dsDNA 
dissociates into ssDNA. Caused by the SYBR®-Green, the fluorescence signal drops at this 
point, creating a peak in the out coming data. In case of primer dimers multiple peaks are 
detected. Reliable qPCR only show one peak. 
 
3.1.8.6 qPCR Evaluation 
The results are described by their Ct values. The Ct values are the number of cycles needed to 
reach a defined threshold of amplified DNA. The Ct value is depended on the initial amount 
of cDNA of the analyzed sequence. Less cDNA results in higher Ct values because more cycles 
have to be done to reach the defined DNA amount. 
 
For analysis of the Ct data two different methods are possible, the quantitative analysis and 
the relative analysis. For the quantitative analysis the Ct values of the gene of interest are 
compared to a dilution line of a known gene concentration. From the values of the known 
gene concentration a standard curve can be made and the absolute RNA content of the 
requested gene can be estimated. Since it is unreliable to compare at least two different cell 
types with this method, the relative analysis is more suitable for this approach.  
The relative analysis compares the Ct values of the requested gene with a housekeeping 
gene to normalize the data. As housekeeping gene an elementary gene of the cellular 
function was chosen, β-actin. β-actin is one of the non-muscular cytoskeletal actins and a 
highly conserved protein. From this and assuming that the amplification of the PCR is 
exponential and the primers are equally efficient the expression was calculated by the 
following equations by the ΔΔCt method.  
              (eq 7) ΔΔCt 
ΔCt (A) = Ct (cell population A) – Ct (housekeeping gene population A) 
ΔCt (B) = Ct (cell population B) – Ct (housekeeping gene population B) 
 
-> ΔΔCt = ΔCt (A) – ΔCt (B) 
Fold expression = 2 
-ΔΔCt
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3.2 Usability of stent design and properties for tissue covered stents 
A lot of stents show a long foreshortening during crimping which would lead to tissue 
damage of the coating. Therefore, different stent structures were tested mechanically and 
for coating and crimping.  
 
 
Figure 19: Process line for stent evaluation. From top to down the tested stent structures,  
the mechanical testing, the molding and conditioning, crimping and analysis is shown. MD 
= mesh density; SMC = smooth muscle cell; FB = fibroblast. 
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In figure 19 an overview of the setup is given. Nine different stents were tested based on 
four different stent types including subgroups. In first place the stents were tested for 
molding and conditioning, proven macroscopically and microscopically (SEM). The protocols 
are already described in chapter 3.1.. Subsequenly, crimping and release tests were 
performed. Additionally, mechanical testing of radial force and bending stiffness was done 
on the knitted stent. Detailed protocols are described below. 
 
3.2.1 Stent development  
The used stents were kindly produced by the Institut für Textiltechnik RWTH Aachen (ITA). 
The stent were fabricated using a 76 µm thick Nitinol wire (NiTi Nr.1SE; FortWayneMetals, 
Indiana, USA). In case of the composite stents additional PVDF was used. In total 9 different 
stent structures were tested. Two composite structures based on a PVDF mesh surrounded 
by easer nitinol rings or a nitinol spiral. Furthermore three braided stents with different 
mesh density of 1, 2 and 3 mm were used. One 3D-stent was used which is composed of a 
braided structure with an additional longitudinal strut. The main focus was on knitted stents. 
Four different knitted stents were tested which can be distinguished by their underlap and 
their mesh density. The meshes are based on two bindings, the plain and the tricot binding, 
which differ in the underlap (Figure 20). The used tricot stents are based on tricot binding 
alone, the used Charmeuse stents are based on a combination of tricot and plain binding. An 
overview is given in table 10.  
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Plain Tricot 
  
Figure 20: Schematic of plain and tricot binding for stent production. The plain structure 
shows a longer underlay compared to the tricot structure. 
 
Table 10: Stent structures and their binding 
Name Binding  Mesh density [meshes/cm] 
Tricot 7 Double Tricot 7 
Tricot 10 Double Tricot 10 
Charmeuse 5 Plain and Tricot 5 
Charmeuse 7 Plain and Tricot  7 
 
The stents were produced on the double raschel warp knitting machine (Karl Mayer, 
Obertshausen, Germany). After knitting the stents, they were dragged on a rod with a 
defined outer diameter of 6 mm and were heated up to 500 °C for 15 min inside a high-
temperature kiln (Heraeus, Langenselbold, Germany). With this step the super elastic 
properties of the stent were established. Afterwards the stents were cut into the desired 
length. Before use, the stents were cleaned and sterilized. For cleaning, the stents were 
washed for 15 min in 100 % ethanol and for 15 min in distilled water. For sterilization the 
stents were autoclaved (2540 EL, Systec). 
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3.2.2 Mechanical testing 
The mechanical testing was thankfully performed by Cristina Käsbauer who wrote her 
diploma thesis in a close cooperation between the ITA and the AME. Her thesis was 
supervised by Valentine Gesché and me. 
The mechanical properties of the stent were tested according to DIN EN ISO 25539-2(85). In 
the DIN the mechanical properties for vascular stents are described and appropriate 
inspection procedures are suggested. The radial force and bending of the stent was tested 
accordingly. Additionally, a 4-point-bending test was performed (table 11). For all test the 
stents were washed and sterilized. In each test 6 new stents were evaluated. For 
measurements of the radial force and bending, the tensile tester Z2.5 (Zwick Roell, Ulm, 
Germany) was used. For the force detection, the 10 N force sensor (Zwick Roell) was used. 
The measured data were digitalized by the program zwick-TestXpert.II. 
 
Table 11: Overview of performed mechanical testing in schedules(21). From left to right: 
radial force test during expanding; bending test over defined radius; 4-point-bending-test. 
Radial force bending 4-point-bending 
 
  
 
3.2.2.1 Radial force 
Applying radial force is one of the main tasks of the stent to hold the vessel open. It was 
measured by a device consisting of two movable V-appliances. The stent was placed in 
between by its smallest diameter (4 mm) following the instruction for use (IFU). Then the V-
appliances are moved apart until the largest diameter of the stent was achieved. This was 
performed with a homogeneous velocity. The radial force was measured by the function of 
stent stent stent 
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the diameter. Subsequently the V-appliances were moved to their original position and the 
stent was crimped to its smallest diameter again (4mm). The force was measured as well. 
According to the norm, the radial pressure was calculated by the measured force and the 
provable cylindrical surface. The setup is shown in figure 21. 
 
 
 
 
 
Figure 21: Radial force setup. The stent was crimped and placed between two movable V-
appliances. The force needed for deformation was measured by a sensor(21). 
 
3.2.2.2 Bending 
The bending/kinking of the stent was measured by bending the stent over defined 
diameters. Therefor the stent was placed inside a silicon tube. The tube with the stent was 
bent over cylinders with radii of 26, 17, 14 and 11 mm. The diameter of the stent was 
measured using an ultrasound device (Vivi I, General Electric, Farfild, USA). For proper 
measurement the tube was filled with water. In figure 22 a schedule is shown.  
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Figure 22: bending / kinking schematic. The stent was placed on cylinders with defined 
diameter. Using an ultrasound sensor, images of the stent during bending were made and 
the stent diameter was measured on the images afterwards(21). 
 
3.2.2.3 4-point-bending test 
With the 4-point-bending test the bending stiffness was evaluated. The bending stiffness 
gives an impression of the wall stress. Higher bending stiffness results in poor wall coverage 
and also irritation and traumatization of the vessel wall.  
In figure 23 the setup is shown. The stent was placed on the ends of two movable rods (A 
and D). The rods were able to move up and down and seesaw over fixing points. A force F 
was put on both rods at B and C, by that the rods seesaw in U by angle α. The bending 
stiffness (El) was calculated by the equation 
 
 EI
L∙F
12∙α
  ,                                         (eq 8) 
4 point bending test 
the force F and distance U were measured, the length of the system and of the rod was 
known. The angle α was calculated by 
 α= tan-1
U
Ls
   .  
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Figure 23: 4-point-bending test schematic(86). The stent was fixed by two rods at both 
ends. The rods are movable in an angle α which leads to a bending of the stent. 
 
Remarkable in this method is the constant bending moment at the stent and that the shear 
force was zero. 
 
3.2.3 Stent crimping 
For crimping, two different methods were tested: the crimping by funnel and the crimping 
by compression. For the in vivo experiments the funnel was used. 
 
For crimping by funnel, the stents were dragged through a handmade funnel (figure 24) of 
12 F inner diameter, reducing the outer diameter of the stent from 6 mm to 4 mm. By 
pushing the stent through the funnel it was delivered and expanded autonomously.  
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Figure 24: Crimping method using a funnel. The stent was dragged through the funnel, 
leading to a final diameter of 4 mm. 
 
Not all stents can be dragged through a funnel. Another option is to crimp the stent by 
compression. Pre-experiments were done by a handmade system using a tube cut 
lengthwise and wrapped around the stent. For further experiments a commercial crimp 
device (HV200, Machine Solutions) which uses a segmental compression mechanism (figure 
25) was used. 
 
 
 
Figure 25: Crimping method using a segmental compression mechanism. On the left, the 
crimping device HV200 (Machine Solutions) is shown. The device is based on a segmental 
compression mechanism. A schematic view is shown on the right. 
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3.3 Suitable scaffold material ELR as an alternative for fibrin-gel 
There are a lot of different materials used in tissue engineering. In this thesis the two 
hydrogels fibrin and elastin-like recombinamers were tested as scaffold. Those scaffolds 
were chosen because of their biocompatibility, easy molding ability and elasticity. For the 
BioStent the scaffolds have to prove the ability for endothelialization and the endothelial 
cells have to resist flow conditions without detachment. This was tested by bioreactor 
conditioning and subsequent cell staining. As fibrin is already approved for stent coverage 
and was also used on the stents in chapter 3.1 and 1.1 here the analysis of elastin-like 
recombinamers as an alternative is shown.  
 
 
Figure 26: Process line of elastin-like recombinamer (ELR) evaluation in comparison to 
fibrin gel as scaffold for the BioStent. Top down the gel production, molding and 
conditioning and analysis is visualized. Tests were performed in well plates (static 
conditions) and on stent in the bioreactor system (flow conditions). Used polymers for 
ELR-gels were VKV a non-specific adhesion protein, RGD a cell adhesion protein and REDV 
a cell adhesion protein with specific attraction to endothelial cells. 
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In figure 26 an overview of the process line is given in direct comparison to the standard 
fibrin-gel protocol. Instead of preconditioning with SMC/FB (fibring-gel) for the ELR-covered 
stents the EC can be seeded direct on the scaffold. Three different gels were used 
differenced by the functional groups VKV, REDV and RGD. The ELR-gels were tested under 
static and under flow conditions. For static evaluation the cells were seeded in cell culture 
plates coated with ELR-gels. For flow experiments stents were covered with ELR-gels and 
seeded with EC. The stents were cultivated in the bioreactor system for one week. For 
analysis, the cells were stained with life and dead staining. Protocols for cell culture, molding 
with fibrinogen and endothelialization are already described in chapter 3.1. Protocols on 
fibrin-gel preparation, ELR-gel preparation and molding as well as life and dead staining are 
described below. 
 
3.3.1 Fibrin-gel production 
For the experiments, commercial fibrinogen was used. Only for the animal trials ovine 
fibrinogen (Sigma) was used, for other experiments human fibrinogen (Calbiochem) was 
used. 
 
3.3.1.1 Ovine fibrinogen 
The fibrinogen was dissolved in purified water at room temperature for 2 h. An amount of 
20 mg/ml was used. After dissolving, it was dialyzed against tris buffered saline (TBS) 
overnight. A dialyze-membrane of 6,000-8,000 MW (Novodirect, Kehl, Germany) was used. 
The next day the content was measured by a Tecan plate reader (Infinite M200, TECAN) at 
280 nm and adjusted to 10 mg/ml with TBS.  
 
3.3.1.2 Human fibrinogen 
The fibrinogen was dissolved in purified water at 37 °C for about 2 h. Afterwards, it was 
dialyzed over night against Tris buffered saline (TBS). A dialyze-membrane of 6000-8000 MW 
(Novodirect, Kehl, Germany) was used. The next day the content was measured by a Tecan 
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plate reader (Infinite M200, TECAN) at 280 nm and frozen at -80 °C until use. For use the 
fibrinogen was unfrozen in a 37 °C water bath. Before use the content was measured by a 
Tecan plate reader (Infinite M200, TECAN) at 280 nm and adjusted to 10 mg/ml with TBS.  
 
3.3.1.3 Fibrin-gel formation 
For the coating 1.5 ml fibrinogen per stent was prepared. Additionally 1 ml TBS with cells 
with 250 µl Thrombin (40 U/ml, Sigma) and 250 µl CaCl2 was prepared. By adding the 
components, the gel was formed in a few seconds and reached its final polymerization after 
about 40 minutes. 
 
Table 12: Composition for fibrin-gel 
 Solution Amount 
Solution A Fibrinogen 1500 µl 
Solution B TBS with cells 1000 µl 
CaCl2 250 µl 
Thrombin 250 µl 
 
3.3.2 Elastin-like recombinamers (ELR) for coverage 
The elastin-like recombinamer (ELR) hydrogel was developed by Prof. José Carlos Rodriguez-
Cabello from the Bioforge Group, University Valladolid in Spain. In close cooperation, first 
experiments for BioStent coverage with ELR were performed. 
The elastin-like recombinamers (also known as elastin-like polymers, ELP) are highly 
biocompatible, can build physically and chemically cross-linked gels and can be 
functionalized with specific sequences to aim the wanted physical and biological properties. 
The ELR are based on natural elastin produced by recombinant techniques.  
Three different polymers were used containing different functional groups. Used polymers 
for ELR catalyst free click gels (CFCG) were VKV a non-specific adhesion protein, RGD a cell 
adhesion protein and REDV a cell adhesion protein with specific attraction to endothelial 
cells. The amino acid sequences for the three proteins are shown in table 13. 
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The gel formation was performed by a catalyst free click reaction between the azid group 
and the activated cyclooctine group of two polymers.  
 
Table 13: Amino acid sequences of the polymers used for ELR production. 
Polymer Amino acid sequence 
VKVx24 MESLLP VG VPGVG [VPGKG(VPGVG)5]23 VPGKG VPGVG VPGVG VPGVG VPGV 
HRGD6 MGSSHHHHHHSSGLVPRGSHMESLLP 
[(VPGIG)2(VPGKG)(VPGIG)2]2AVTGRGDSPASS[(VPGIG)2(VPGKG)(VPGIG)2]2 
REDVx10 MESLLP[(VPGIG)2(VPGKG)(VPGIG)2EEIQIGHIPREDVDYHLYP(VPGIG)2(VPGKG)(VPG
IG)2(VGVAPG)3]10V 
 
3.3.2.1 ELR gel formation 
For ELR gel formation the azid group and the activated cyclooctine group was dissolved 
separately in purified water at 4 °C for at least 24 h. An amount of 75 mg/ml was used. The 
molding of the stents was performed using a two syringes injection system. The mold 
consists out of a silicone tube (inner diameter 8 mm) and an inner cylinder (outer diameter 
5.5 mm), made out of polytetrafluorethylene (PTFE; Kuempel-Kunststoff-
Verarbeitungswerk). In figure 27 the molding process is visualized. The mold and the 
syringes were brought to 4 °C prior to the experiment. The molding process was performed 
at 4 °C. After 15 min the system was brought to room temperature. For sterilization the 
stents were exposed to UV-light for about 4 h. Afterwards the gel was washed in PBS for at 
least 1 h plus another 2 h in fresh PBS. A final hydration in PBS was performed for about 
24 h. For cell coating 10x10
6
 HUVEC per ml were used. For the endothelialization protocol 
see 3.1.4. 
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Figure 27: Schematic representation of the ELR-BioStent molding. The elastin-like 
recombinamer gel (ELR) is based on an azid group and a cyclooctine group which 
polymerize by mixing. For molding a tubular structure out of an inner and outer cylinder, 
with the stent inside was used. The ELR catalyst free click gels (CFCG) can be combined 
with bioactive sequences and be endothelialized afterwards(66). Reprinted from Acta 
Biomaterialia, Israel González de Torre, Frederic Wolf, Mercedes Santos, Lisanne Rongen, 
Matilde Alonso, Stefan Jockenhoevel, José C. Rodríguez-Cabello, Petra Mela, Elastin-like 
recombinamer-covered stents: Towards a fully biocompatible and non-thrombogenic 
device for cardiovascular diseases (2014), with permission from Elsevier. 
 
3.3.3 Live and dead staining on elastin-like recombinamer (ELR)-gels 
For live and dead staining the LIVE/DEAD® Viability/Cytotoxicity Kit for mammalian cells 
(Molecular Probes™, Cat. No. L3224) was used. The growth of human umbilical vein 
endothelial cells on ELR-gels (HUVEC) was determined by the live and dead staining. The test 
was performed on cell culture samples as well as on covered stents after bioreactor 
cultivation.  
For the cell culture test, 30 µl gels (15 µl 75 mg/ml ELR-cyclooctine + 15 µl 75 mg/ml ELR-
azide) were prepared in a 96-well-plate. Four different gels were prepared in triplicate for 
ELR with bioactive sequence 
ELR with bioactive sequence 
azide 
cyclooctine 
ELR-cyclooctine with 
bioactive sequence 
ELR-azide with 
bioactive sequence 
HUVECs 
stent 
ELR-
BioStent 
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(ELR-catalyst free click gels) 
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each measure time point. Prepared gels are VKV-24-CFCG, REDVx10-CFCG, RGDREDV-CFCG 
and HRGD6-CFCG. The gels were sterilized by UV-light for about 3 h and washed with 
medium for at least 2 h. On each gel 2500 HUVEC were seeded and supported with medium 
(EGM-2, Lonza). As positive control served a gelatin gel with HUVECs. The negative control 
was a VKV-24-CFCG gel without cells. The live and dead staining was done after one, five and 
nine days.  
The protocol was done according to the manufacturer’s instruction. A concentration of 4 µM 
EthD-1 and 2 µM calcein-AM was added to all samples. After 3.5 h incubation time the 
fluorescence emission of calcein-AM was measured at 530 nm and of EthD-1 at 645 nm. The 
bioreactor samples were cut and stained in the same way as the gels right after cultivation of 
one or two weeks. 
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3.4 Proof of function in vitro 
The hemocompatibility was tested in a chandler loop system with human blood. For analysis 
specific platelet staining and SEM imaging was performed. The experimental process-line is 
shown below (Figure 28).  
 
 
Figure 28: Process line for in vitro evaluation. Top down the experimental workflow is 
shown. Five stents were tested under different conditions: with and without crimping, 
with and without EC and with and without blood contact. As control, a Gore-Tex® 
prothesis was used. SMC = smooth muscle cell; FB = fibroblast; EC = endothelial cell; SEM = 
scanning electron microscopy. 
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The setup is constructed by cell culture preparation followed by molding and conditioning 
with a final blood test in the chandler loop system. Nitinol knitted stents (tricot 7) from ITA 
were molded with fibrin-gel and included SMC/FB. The stents were endothelialized with 
human endothelial cells from umbilical cord veins (HUVECC). The cell culture, molding and 
conditioning is already described in chapter 3.1.. Six different conditions were tested as 
follows:  
 
1. BioStent with EC without blood contact as control  
2. BioStent with EC with blood contact with damaged coating 
3. BioStent with EC with blood contact 
4. BioStent with EC with blood contact after crimping and release 
5. BioStent without EC with blood contact 
6. Gore-Tex® with blood contact as control 
 
The stents and the Gore-Tex® prosthesis were placed in the chandler loop system for blood 
incubation for one hour. Afterwards the stents were stained against CD41/61 a specific 
platelet marker. The protocols for the chandler loop and the staining are described in detail 
below. The protocol for the SEM was already described in chapter 3.1.6. 
 
3.4.1 Chandler loop 
A Chandler loop is used for testing blood compatibility. For that, both ends of a silicon tube 
(ID: 6.4mm) were connected by a bigger tube (ID: 8 mm) to form a ring, as shown in figure 
29. The stent was placed inside the tube, which was filled with 7ml of human blood. The 
blood was taken from voluntary donors by a 19 gauge needle and directly led into citrate 
vacuum tubes (3 % citrate) until use. The prepared Chandler loop was placed on the pump 
head of a roller pump and rotated at 76 rounds/min for 1 h at 37 °C inside an incubator. 
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Figure 29: Chandler loop system: rotational tube system for blood compatibility test. The 
tested stents rotated for one hour. The shear stress imposed by the blood flow was 1 Pa. 
 
Calculation of the shear stress in the Chandler loop system: 
The shear stress () can be correlated to the shear rate () and the dynamic velocity (µ) as 
described before (chapter 3.1.5). 
For the used 6 ml volume and 7.69 rpm the flow rate is   = 7.69∙10-6 m3/s. The flow rate   
and the radius of the inner tube diameter r=0.00275 m can be inserted into the shear rate 
equation (eq. 5). 
 
4


4 ∙ 7.69 ∙ 10  m/s
(0.00275m)
 489.8 s& 
 
The shear stress is correlated to the fluid viscosity. For the experiments human blood was 
used which has a viscosity of 3 to 4∙ 10 Pa s.  
Integrating the shear rate and the blood viscosity of 3.5∙ 10 Pa s into the shear stress 
equation, results in a shear stress of about 1.71 Pa. 
 
   ∙ 
  489.8s& ∙ 3.5 ∙ 10Pa ∙ s  1.71 Pa 
 
The mean wall shear stress in human, irrespective of caliber and function of the vessel, is 
about 1.5Pa(87). 
 
76.9 rpm 
Pump head 
Connector tube 
(1 Pa; ~300 ml/min) 
Stent 
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3.4.2 Staining of platelets 
A primary CD41/61 complex antibody (Acris) was used for platelet staining. The stents 
treated with blood were stained for negative control the primary antibody was omitted. For 
secondary antibody Molecular Probes Alexa Fluor 488 (Invitrogen, A11001) was used. A 
fluorescent microscope from Zeiss was used (AxioObserver Z1; Carl Zeiss GmbH; AxioCam 
MRm; Carl Zeiss GmbH). The stepwise protocol is given in the appendix. 
 
 
Material and methods 
86 
3.5 Proof of function in vivo 
As final proof of concept the implantation in healthy sheep was addressed. After three 
months of implantation a patent and still entothelialized stent without thrombosis was 
expected. For proof the stent were implanted inside carotids in first place and as an 
interponate in further experiments. The experimental setup is visualized in figure 30.  
 
 
Figure 30: Workflowe of in vivo experiments. 
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Two autologous stents were produced for each sheep. For the autologous coating cells were 
harvested from sheep. Therefore, in a first operation a piece of carotid was explanted and 
the carotid was reconnected by end-to-end anastomosis or a Gore-Tex® prosthesis was 
inserted. Out of the tissue sample, endothelial cells and SMA/FB cells were isolated (chapter 
3.1). A warp knitted stent, manufactured by the ITA, was coated with commercial sheep 
fibrin-gel including the SMC/FB (chapter 3.1.3). The EC were seeded inside the lumen 
(chapter 3.1.4). A conditioning phase was done inside an incubator for at least three weeks. 
During the conditioning, the stents were flushed with cell culture medium under pulsatile 
flow conditions (chapter 3.1.5).  
Before implantation the two stents were macroscopically assorted in regard to wall 
thickness and homogeneous coating. The stent with the thinner coating without holes or 
irregularities was chosen for the in vivo experiment. The second choice of stent was 
embedded for analysis as in vitro control directly (figure 31). 
 
 
 
 
Figure 31: Decision of stent for in vivo study. The best stent in regard to a thin and 
homogeneous tissue coating was macroscopically analyzed and chosen for in vivo study. 
The second stent was used as in vitro control. 
2 stent/sheep 
implantation In vitro evaluation 
first choice 
Decision 
of the best 
second choice 
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The stents chosen for implantation were crimped by funnel (chapter 3.2.3) and transported 
in cell culture medium to the operation room. In the first three sheep (I-III) the stents were 
inserted into the carotid using a 12 F catheter and ejected with a pusher.  
Because of early stent occlusion due to low radial resistance of the stent structure the setup 
was changed afterwards (figure 32). In the next five (1-5) sheep the stents were inserted as 
interponate to circumvent the low radial resistance. The stents were still crimped and 
released before implantation to simulate the mechanical requirements of the process. For 
implantation a piece of carotid was explanted and the stent inserted and fixed by stitching.  
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Figure 32: Visualization of the different implantation types. Top: implantation of the stent 
inside the carotid artery using a catheter. Bottom: implantation of the stent as an 
interponate in between the carotid artery. 
 
For monitoring, ultrasound measurement was done periodically. Additionally, angiography 
was done before the stent was explanted for laboratory analysis. An overview of the whole 
setup is shown in figure 33, including the cell harvesting from the sheep, the stent molding 
with SMC/FB cells and fibrinogen, first conditioning in the bioreactor, endothelialization of 
the stent surface, second conditioning in the bioreactor, implantation, monitoring and final 
explantation. In table 14 an overview of the conditioning time and implantation time of each 
sheep is given. 
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Figure 33: Experimental setup: The setup shows the different steps included in the process 
starting by the cell harvesting, followed by cell growth, stent coating and conditioning and 
finally implantation, monitoring and analysis. 
 
Table 14: Conditioning time of the implanted stents 
Animal Pre conditioning 
[days] 
Final conditioning 
with EC [days] 
In vivo [days] Total [days] 
I 14 7 104 125 
II 14 7 35 56 
III 20 - 28 48 
1 13 8 69 90 
2 15 17 89 121 
3 21 17 97 135 
4 14 7 73 94 
5 14 7 69 90 
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3.5.1 Animal treatment 
All experiments were performed according to the German legislation governing animal 
studies, following the Principles of Laboratory Animal Care (NIH publication. 85-23, revised 
1996). Prior to the study an animal treatment proposal was prepared and authorized by the 
governmental animal care and use office (reference number 87-51.04.2010.A351; Landesamt 
für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen, Recklinghausen, Germany). 
The sheep were ordered from a disease-free barrier breeding facility. The care for the sheep 
during the experiments was performed by animal care attendant and veterinarian of the 
Institute for Laboratory Animal Science (Institut für Versuchstierkunde). The sheep lived in 
the institute farm during the project. 
 
3.5.2 Animal model 
For the in vivo study Rhön and Merino sheep were chosen. Sheep of different species were 
used because of limited availability. Sheep are a common model in the cardiovascular 
research. Furthermore, the handling is easy. Male and female sheep were used (table 15). 
There is no influence expected in regard to the sex or the species.  
 
Table 15: Overview of the involved animals. 
Animal Registration number Sex Species Weight [kg] 
I 7434 female Rhön sheep 43.8 
II 83205 female Rhön sheep 59.6 
III 83329 female Rhön sheep 60 
1 83166 female Rhön sheep  71 
2 577 male Merino sheep 78 
3 578 female Merino sheep 65 
4 16512 female Rhön sheep 75 
5 28347 female Rhön sheep 66 
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3.5.3 Anesthesia 
For the invasive surgery, like cell harvesting, stent implantation, explantation and 
angiography, the sheep were anaesthetized. The animals have been premedicated with 
Atropin 1 % (0.1-0.5 mg/kg), Rompun 2 mg = 0.1 ml/kg and Propofol 0.26 ml/kg. During the 
operation, the sheep were intubated endotracheal for breathing support. The anesthesia at 
operation time was done by isuflurane (1.5 Vol %) and fentanyl (0.2 mg/kg/h). Before 
clamping the carotid during operation, 5000 units Heparin were applied. 
 
3.5.4 Biopsy 
For autologous cell harvesting from each sheep a 3 cm long piece of carotid was explanted. 
Instead a Gore-Tex® graft (W.L Gore & Associates, Newark, Delaware, USA) was implanted. 
Under anesthesia, the carotid was clamped proximal and distal of the explantation point and 
a 3 cm piece was cut out. The Gore-Tex® prosthesis was inserted and fixed surgically. The 
wound was closed layer by layer.  
The explanted piece of carotid was placed into transport buffer (100 mM HEPES, 140 mM 
NaCl, 2.5 mM KCl, 10 mM glucose, 1 % antibiotic/antimycotic solution (penicillinG/ 
streptomycin/amphotericin B; Gibco, Karlsruhe, Germany)) immediately. The sheep were 
treated with Aspirin (100 mg; Bayer Medicin AG, Leverkusen, Germany) daily after surgery. 
 
3.5.5 Implantation 
The pre-cultured stent were implanted into the non-treated carotid of the donor animal. As 
described in the setup, the first three stents were implanted inside the carotid artery and 
the following 5 stents were implanted as an interponate in the carotid artery. All stents were 
crimped prior to implantation. 
 
3.5.6 Angiography 
Angiography is an invasive x-ray imaging procedure using contrast agent to visualize blood 
vessels. The patency of the stents was proven by angiography at the end of the experiment. 
The sheep were anaesthetized and treated with 5,000 units Heparin. The introducer sheath 
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was inserted into the carotid proximal to the stent. A contrast agent was applied (Ultravist-
300, Bayer, 80811853). The imaging was done using the C-arm X-ray unit Arcadis Orbic 3D - 
System from Siemens. A substraction in fluoroscopy of 6 frames/sec was performed. The 
imaging was visualized by the syngo fastView software (Siemens). 
 
3.5.7 Ultrasonography 
Regular ultrasonography (US) was done on the sheep. No anesthesia was needed. The sheep 
were sound in the group to minimize stress. A color/directional doppler ultrasound was done 
using the Vivid I from GE Healthcare (Munich, Germany). 
 
3.5.8 Explantation 
The observation period was about 86±8 days. At the end a last sonography and angiography 
was performed and the stents were explanted. The sheep were under anesthesia during the 
process and were euthanized in the end by pentobarbital (50-80 mg/kg; Marial GmbH, 
Hallbergmoos, Germany). The stents were immediately placed into transport buffer until 
further preparation.  
Photo documentation was done before the stent was cut length to observe the lumen. For 
the different analysis methods the stent was cut and fixed in glutaraldehyde for SEM-
imaging, in RNA-later for PCR analysis and in Carnoy for further embedding in PMMA for 
slices. 
 
3.5.9 Fixation and embedding  
For histological and immunochemical staining the stent were fixed in Carnoy’s solution and 
embedded in PMMA. First the samples were washed gently with PBS and fixed in Carnoy’s 
solution (60 % ethanol, 30 % chloroform, 10 % acetic acid) for 2 h. Afterwards the fixative 
was removed and the samples were washed twice in ethanol absolute for 15min. 
The fixated samples were dehydrated inside an automatic dehydration device (Leica, 
TP1020) passing through increasing isopropanol solutions ending in xylol (table 16). 
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Table 16: Dehydration line inside the dehydration device.  
Station Concentration Chemicals Duration 
1 30 % Isopropanol 1 h 
2 50 % Isopropanol 1 h 
3 80 % Isopropanol 1 h 
4 90 % Isopropanol 1 h 
5 100 % Isopropanol 1 h 
6 100 % Isopropanol 1 h 
7 100 % Xylol 1 h 
8 100 % Xylol 1 h 
 
After dehydration the stents were embedded in polymethylmethacrylat (PMMA, Technovit 
9100, Heraeus). To achieve a slow infiltration of the PMMA three pre-infiltration steps were 
completed (immersion) followed by the embedding (table 17). The stents were placed in 
cylindrical molds without air contact for the embedding process. For polymerization the 
samples were stored in an ice cooled water bath at least overnight. The optimal 
polymerization can be achieved at -20 to -8 °C. 
 
Table 17: Embedding protocol PMMA Technovit 9100. 
Station Concentration Chemicals Duration 
Pre-infiltrations 1 50 % 
Xylol/Technovit 9100 basis 
solution 1 h 
Pre-infiltration 2 - 
Technovit 9100 basis solution + 
hardener 1 1 h 
Pre-infiltration 3 - 
Technovit 9100 basis solution + 
hardener 1 1 h 
Infiltration - Stock solution A + B Over night 
Stock solution A - 
Technovit 9100 basis solution + 
hardener 1 + PMMA - 
Stock solution B - 
Technovit 9100 basis solution + 
hardener 2 + regulator - 
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3.5.10 Thin section 
For sectioning the in PMMA included stents, they were glued on a plastic slide for better 
handling. To reinforce the attachment the slide was first roughened by a micro grinding 
device (Exakt, Norderstedt). For glueing, fast hardening cold polymerization plastic glue 
(Heraeus Kulzer, Technovit 4000) was used. In a second step a glass slide was glued (Heraeus 
Kulzer, Technovit 7230 VLC) on the other side using UV-light for photo polymerization. Now 
the stent was cut close to the glass slide and grinned and polished until a thin section of 20-
30µm was achieved. Another glass slide can be glued on the stent and further thin sections 
were produced. 
 
3.5.11 Histological staining – hematoxylin & eosin (H&E) of PMMA slides 
The H&E-Staining gives a comprehensive view on the cell distribution and nuclei-plasma 
relation. This double staining method consists out of the hematoxylin staining of acetic 
structures like DNA in blue and staining of positive charged parts like cytoplasm in red.  
For the staining the slides were placed on a 60 °C heating plate and covered with 
hematoxylin (Merck 1.09249.0500) for 12 min. Thereafter, the slides were flushed with 
water for about 30 min. Eosin Y was mixed with acetic acid (1000 µl eosin Y, Sigma HT110-2-
16 + 5 µl acetic acid). The slides were placed on the heat plate again and covered with the 
prepared eosin Y solution for 1 min. A washing step of 5 min under floating water was 
performed. After drying, the samples were covered with euparal (Roth 7356.1) and cover 
slides. A Zeiss microscope was used for imaging (Axioimager D1; Carl Zeiss GmbH, Jena, 
Germany; AxioCam Mrc; Carl Zeiss GmbH). 
 
3.5.12 Immunohistochemical staining of PMMA slides 
The immunohistochemistry is based on specific antigen-antibody-reactions. The antibody is 
coupled to a detection system like a fluorescence signal. By increasing the signal also very 
little amounts of epitopes can be detected.  
In this staining an indirect (two stage) method was used. The staining consists out of two 
components: the first antibody which is specific to the epitope and a second antibody, 
carrying the fluorescent marker and is specific to the host of the first antibody. This method 
allows an increase in the binding of the antibodies and therefore a higher signal. Compared 
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to a single stage staining, where the first antibody is directly marked, this method is more 
sensitive. 
Starting the staining the PMMA embedded slides were deplasted followed by a blocking step 
and the staining (table 18). For proving the specificity, negative controls were made by 
leaving the primary antibody out. As positive controls native tissue samples were used. A 
fluorescent microscope from Zeiss was used for imaging (AxioObserver Z1; Carl Zeiss GmbH; 
AxioCam MRm; Carl Zeiss GmbH) 
 
Table 18: Immunohistochemical staining. 
 Step Chemical Dilution Duration 
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1 Xylol 100 % 3x20 min 
2 Methoxyethylacetat 100 % 20 min 
3 Aceton  100 % 10 min 
4 Aqua dest 100 % 5 min 
S
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5 Normal goat serum 5 % 1 h 
6 Primary antibody Table 19 1 h 
7 PBS with triton 0.1 % 3x5 min 
8 Secondary antibody 1:400 1 h 
9 PBS with triton 0.1 % 3x5 min 
10 DAPI 1 µg/ml 5 min 
11 PBS with triton 0.1 % 3x5 min 
12 Fluorescent mounting medium - - 
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Table 19: Antibodys for immunohistochemical staining. 
 Target Host Fluor Dilution 
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 αSMA Mouse - 1:400 
Collagen I Rabbit - 1:100 
vWF Rabbit - 1:100 
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Mouse Goat Alexa Fluor 594 1:400 
Mouse Goat Alexa Fluor 488 1:400 
Rabbit Goat Alexa Fluor 594 1:400 
Rabbit Goat Alexa Fluor 488 1:400 
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4 Results 
4.1 Evaluation of the source of endothelial cells.  
There are two common sources for endothelialization: first, adult endothelial cells from the 
blood vessels and second, endothelial progenitor cells out of the blood. Both cell types were 
evaluated as stent coating. Another common problem is the trans- or dedifferentiation of 
cells in culture over time. A decision has to be made until which passage the cells are still 
usable. A lower number of usable passages correlated to a larger number of cells to isolate in 
the first place. The results for EPC and EC coating are shown below. The analysis in regard to 
transdifferentiation was done on human endothelial cells. 
 
4.1.1 Human endothelial progenitor cells (EPC) for coating  
Early human EPC were used for coating. The cells were isolated out of blood and cultivated 
for three days prior to coating. The cells were labeled with DiI-Ac-LDL, here seen in red 
(figure 36). After conditioning in the bioreactor for 7 days, the cells were detected on the 
surface. The SEM images show the stent surface lined with cells. The cells are long shaped 
cells and round cells with long cytopodium.  
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EPC in culture BF + FL EPC on stent BF + FL SEM image 150x 
 
EPC in culutre FL EPC on stent FL SEM image 600x 
 
 
Figure 34: Human EPC stained with DiI-Ac-LDL in culture and on the stent surface. BF = 
bright field, FL= fluorescence. 
 
4.1.2 Ovine endothelial cells (EC) for coating 
Primary ovine EC were used for coating. The cells were isolated out of ovine carotid and 
cultivated for several weeks until passage 4. The endothelialized stents were analyzed after a 
conditioning time in the bioreactor of 4, 6 and 8 days. Using scanning electron microscopy 
(SEM) the confluence of the cell layer was analyzed. In figure 35 the stent surface is seen. 
The cells of all three cultivation times are well attached. At four days there are still empty 
places. From day six on a confluent endothelial layer was observed. The surface is smoother 
compared to the EPC coating (figure 34). 
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Figure 35: After endothelialization the stent was cultivated. The scanning electron 
microscopy images show the stent surface after 4, 6, and 8 days of cultivation.  
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4.1.3 Endothelial cell harvesting from ovine carotids 
For isolation optimization two different medium were tested for cell cultivation right after 
cell isolation. Three carotids were used and each cut in 6 pieces. Three pieces were treated 
with medium from PAA and three with medium from Lonza. The grown colonies were 
counted over two weeks to compare the efficiency. In figure 36 the number of colonies is 
shown, two weeks after isolation. In the medium of Lonza in more cases colonies are grown 
and also more colonies in total grew. There was a high variance in between the different 
carotids isolated despite the used medium. 
 
 
Figure 36: Counted colonies of primary endothelial cells harvested from ovine carotid, two 
weeks after isolation. Three carotids were used (1-3) with each three samples. After 
isolation the cells were treated with different medium from Lonza (blue) and PAA (red). 
 
Additionally, the grown colonies were stained against CD31 as an endothelial cell marker 
(figure 37). A positive staining in all cell cultures was detected. The formation of growing was 
not different for the cells of one carotid treated with the different medium. 
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EC cultivated in medium of Lonza EC cultivated in medium of PAA 
 
 
Figure 37: Endothelial cells (EC) two weeks after isolation. Left: cells cultivated in medium 
from Lonza and right: cells cultivated in medium from PAA. Cells were stained against 
CD31 (green) a typical EC marker and with DAPI (blue). Scale bars indicate 100 µm. 
 
4.1.4 Transdifferentiation of human endothelial cells in culture  
Cell cultivation is necessary to reach sufficient cell numbers. Nevertheless, by cultivation 
over a long time and several passages the cells might change their morphology and function. 
To analyze changes in cell culture of HUVECs, the cells of three donors were analyzed over 
10 passages in regard to morphology and the specific EC markers CD31, von Willebrand 
factor (vWF), endothelial nitric oxide synthase (eNOS) and kinase insert domain receptor 
KDR (vascular endothelial growth factor receptor-2: VEGFR-2). 
 
4.1.4.1 Microscopic monitoring of human endothelial cells over 10 passages 
The endothelial cells of three umbilical cords were imaged over 10 passages. In figure 38 the 
images of every second passage is shown. As can be seen the shape of the cells in passage 0 
is a typical cobble stone pattern. This remains the same until passage 4. But the shape of 
some cells changed. There are also long shaped cells and big flat cells in culture. 
Furthermore, the cells do not reach confluence anymore in higher passages. 
 
vWF DAPI vWF DAPI 
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Passage 0 Passage 2 Passage 4 
 
Passage 6 Passage 8 Passage 10 
 
 
Figure 38: Microscopic images of human endothelial cells in cell culture over 10 passages. 
Scale bars indicate 200µm(88). 
 
4.1.4.2 Endothelial cell marker genomics and proteomics 
For analysis on gene level, the cells were evaluated over 10 passages. The data are shown for 
every second passage. The expression rate was analyzed for CD31, vWF, eNOS and KDR 
(VEGFR-2). Additionally, on protein level CD31, eNOS and KDR (VEGFR-2) positive cells were 
analyzed using FACS analysis. The gate was set using passage zero, the further passages were 
all measured in this gate.  
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Figure 39: CD31 analysis of three human endothelial cell lines (EC) over ten passages in cell 
culture. Every second passage is show. Top: relative gene expression CD31 relative to 
passage zero. Bottom: FACS analysis of CD31 positive cells in % of gated cells(88). 
 
The relative expression for CD31 compared to passage zero showed a tendency to lose the 
expression over the passages. Although for cell line 1 there was an increase until passage 6 
with a decrease afterwards (figure 39 top). In FACS analysis inside the gate nearly 100 % of 
the cells were positive for CD31 (figure 39 down) and stayed over 10 passages. 
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Figure 40: TOP: KDR (VEGFR-2) analysis of three human endothelial cell lines (EC) over ten 
passages in cell culture. Every second passage is show. Top: relative gene expression KDR 
relative to passage zero. Bottom: FACS analysis of KDR positive cells in % of gated cells(88). 
 
The relative expression for KDR was increased for cell line two, cell line one first increased 
and decreased after passage 6, the last cell line almost showed no signal for the passages 
higher 2 (figure 40 top). The staining against KDR showed in the FACS analysis in only about 
20 % of the cells a positive signal in passage 0 and the amount decreased below 4 % for 
passage 1-6. Thereafter, in one cell line the amount increased and showed the highest 
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amount at passage 8 with 47.9 % in cell line 3. All the other cell lines did not show this 
pattern (figure 40 down). 
 
 
 
 
Figure 41: eNOS analysis of three human endothelial cell lines (EC) over ten passages in cell 
culture. Every second passage is show. Top: relative gene expression eNOS relative to 
passage zero. Bottom: FACS analysis of eNOS positive cells in % of gated cells(88). 
 
The expression of eNOS was for two lines first increased and then decreased after passage 6. 
Line three already decreased at passage 2 (figure 41 top). The staining for eNOS was, except 
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for one measure point, always lower than 3 % in the FACS analysis. A general trend of 
decrease was detected (figure 41 down). 
 
 
 
Figure 42: vWF analysis of three human endothelial cell lines (EC) over ten passages in cell 
culture. Every second passage is show. Relative gene expression of vWF relative compared 
to passage zero(88).  
 
For vWF, the expression was increased for the cell lines one and three. Line 2 instead was 
decreased (figure 42). Analysis on protein level using FACS was not performed due to 
location of the antigen. vWF is located inside the cell, which was not detectable with the 
protocol used for the other markers. 
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4.2 Usability of stent design and properties for tissue covered stents 
A lot of stents show a long foreshortening during crimping. With a tissue covered stent this 
would lead to damage of the tissue. Therefore, special requirements are put on the stent 
structure. There need to be low tissue deformation and at the same time still a strong radial 
force and low bending stiffness. The results for radial force, bending stiffness and crimping 
are shown below.  
 
4.2.1 Influence of stent design on the crimping 
In a first experiment stents made out of nitinol and those made out of a composite of nitinol 
and PVDF were tested. For composite a PVDF mesh was supported by either a spiral out of 
nitinol or several nitinol rings, as nitinol stent a knitted sent was used. The stents were 
coated with fibrinogen and cells (SMC/FB) and were cultivated for three weeks. After 
cultivation, the stents were crimped using a funnel. The composite stents showed huge 
deformations and holes during the crimping. The knitted nitinol stent preserve its structure 
and the coating showed no damage as can be seen in figure 43. 
 
Knitted nitinol PVDF + nitinol spiral PVDF + nitinol rings 
 
 
Figure 43: First crimping test: nitinol (left) versus two composite stents.  
 
In a next step knitted and braided stents were compared in regard to tissue-engineered 
coverage. The three different braided stents were used with a mesh density of one, two and 
three mm. In a first trial, the stents were coated by the standard procedure (chapter 3.1.3) 
but the braided stents deformed during the cultivation period, only the knitted stent showed 
a homogeneous coverage without deformation (figure 44). Therefore, in a second try the 
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braided stents were fixed at the ends by silicon rings to avoid deformation (figure 45). Also 
after fixation the results were not satisfying, big holes in the coating could be observed. To 
prevent the twisting of the struts a braided stent with supporting length wire (3D-stent) was 
tested. As can be seen, this stent showed a nice and complete coverage (figure 45). 
 
Knitted  Braided 1 mm Braided 2 mm  Braided 3 mm 
 
 
Figure 44: Trial 1: tissue engineered stents after 3 weeks of cultivation in the bioreactor 
without fixation. From left to right: knitted stent, braided stents with different mesh 
densities of 1, 2 and 3 mm. 
 
Braided 1mm Braided 2mm 3D 
 
 
Figure 45: Trial 2: tissue engineered stents after 3 weeks of cultivation in the bioreactor 
using silicone rings for fixation at the edges. From left to right braided stent with 1 mm 
mesh density, braided stent with 2 mm mesh density and 3D stent a braided stent with 
supporting longitudinal strut. 
 
The stents from trial 2 were all crimped by segmental compression and additionally analyzed 
by scanning electron microscopy as shown below. As can already be seen in the overview 
the coating of the braided stent was not completely surrounding the stent struts. The 
coating itself was endothelialized. In the two braided stents the endothelial cells are more 
separated and not as smooth as before crimping, compared to the 3D stent. 
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Figure 46: SEM image of tissue engineered, endothelialized braided stent 1 (1 mm mesh 
density), before crimping and after release. 
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Figure 47: SEM image of tissue engineered, endothelialized braided stent 2 (2 mm mesh 
density), before crimping and after release. 
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Figure 48: SEM immage of tissue engineered, endothelialized 3D stent before crimping and 
after release. 
 
4.2.2 Mechanical improvement and characterization of the knitted stent structure 
As the knitted stent showed good behavior for coating and crimping, the mechanical 
properties were analyzed and furthermore some changes to the parameters were 
performed to characterize and compare. Four different stents have been tested 
mechanically at the ITA by Christina Käsbauer under supervision of Valentine Gesché. Two 
stents with the tricot binding with a mesh density of 7 and 10 meshes per cm and two stents 
with charmeuse binding and a mesh density of 5 and 7 meshes per cm were prepared (figure 
49).  
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Binding Charmeuse Tricot 
Photo 
   
Set mesh 
density 
5 7 7 10 
Measured 
mesh density 
7 10 8 13 
Figure 49: Different knitted stents for mechanical characterization from left to right 
Charmeuse 5, Charmeuse 7, Tricot 7 and Tricot 10. The number indicates the mesh 
density(21). 
 
The stents are exposed to different forces during lifetime. To test their ability to withstand 
these challenges, the radial force and bending stiffness were tested. For good performance a 
high radial force and low bending stiffness is aimed. 
 
4.2.2.1 Radial force 
The radial force is of high interest since it gives an impression of the ability of the stent to 
withstand the pressure of the blood vessel and also the fixation to the position in the vessel. 
With too low radial force the stent might be carried away by the blood flow.  
Therefore, the stents were squeezed together and the force during unfolding was measured. 
The measured values are visualized in figure 50. The stent has a diameter of 6 mm when 
completely expanded. The forces are shown for three different diameters. As can be seen for 
all four stents the highest forces were achieved for a diameter of 4 mm, for bigger diameter 
the force dropped below 1.4 cN/mm. At 4 mm Tricot 7 had a radial force of 1.52 cN/mm, 
which was the lowest of the compared stents. It was followed by Charmeuse 5 with 
2.84 cN/mm and Charmeuse 7 with 3.12 cN/mm. The highest radial force achieved Tricot 10 
with 4.78 cN/mm. 
 
1cm 1cm 1cm 1cm
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Figure 50: Radial force measurement at different diameters. Four different stent structures 
were tested: tricot 7, tricot 10, charmeuse 5 and charmeuse 7.(21) A high radial force is 
desired. 
 
4.2.2.2 Bending 
Dependent on the position of the stent it is bended by motion of the body. During bending 
the stent should not kink, also the remaining size of the diameter is of interest. To evaluate 
the diameter during bending, the stent was bended inside a tube on a defined diameter. The 
cross-section of the stent was visualized by ultrasound and the diameter measured in the 
images. Examples of ultrasound images are shown in figure 51. The minimal diameter which 
could be achieved without kinking is visualized in figure 52. For the different bending 
diameters in all cases the Charmeuse 7 had the largest inner diameter.  
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Bending 
diameter 
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- 26 17 14 11 
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Figure 51: Bending diameter measured in ultrasound immages(21). Images show the cross 
section of the stent during bending over cylinders with defined diameter. 
 
 
 
Figure 52: Bending and kinking over defined diameters(21). Four different stent structures 
were tested: Tricot 7, Tricot 10, Charmeuse 5 and Charmeuse 7. 
 
4.2.2.3 4-point-bending test 
Last but not least, the bending stiffness was tested using a four-point-bending test. In this 
test the force needed to bend the stent was measured. The force was detected for three 
different bending points at 0.5 mm deposition, 1 mm and 2 mm. At all different deflections 
the stiffest stent was Tricot 10 with 198.7 Nmm
2
 at 0.5 mm. The second position was Tricot 7 
with nearly half the force, namely 90.7 Nmm
2
. The Charmeuse stents were even less stiff 
with 30.1 Nmm
2
 for Charmeuse 5 and 59.2 Nmm
2
 for Charmeuse 7. 
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Figure 53: Bending stiffness was measured using the 4-point-bending method(21). Four 
different stent structures were tested: Tricot 7, Tricot 10, Charmeuse 5 and Charmeuse 7. 
A low bending stiffness is desired. 
 
4.2.3 In vitro test with tricot 10 and Charmeuse 5 stents (human cells) 
Therefore, with those two stents an in vitro test was proceeded. The stents were coated 
with fibrinogen and SMC/FB and lined with endothelial cells. After three weeks of 
cultivation, the stents were analyzed with SEM.  
In figure 54 an overview of the stents is shown. Seven to eight pictures were stitched 
together to a panoramic image using imaging software (Hugin, version 2011.2.0.3, 
http://hugin.sourceforge.net/). As can be seen in the overview the Tricot 10 stent is coated 
more homogeneously than the Charmeuse 5 stent. Charmeuse 5 shows small drags and at 
the lower part the coating is unsatisfying with big stent parts uncoated.  
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Figure 54: Scanning electron microscopy (SEM) image fused out of several images giving a 
complete overview of the stents. Left: tricot 10; right: charmeuse 5(21). 
 
Having a closer look on the coated surface of the stents both showed a smooth surface with 
confluent endothelial coverage. It can be seen that on the Charmeuse 7 stent the cells 
showed a circular orientation (figure 55). Whereas on the Tricot 10 the cells were more flat 
and spread and show no clear direction (figure 56).  
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Figure 55: Scanning electron microscopy (SEM) image closeup showing the inner surface of 
a tissue engineered and entothelialized charmeuse 5 stent. (21) 
 
 
 
Figure 56: Scanning electron microscopy (SEM) image closeup showing the inner surface of 
a tissue engineered and entothelialized tricot 10 stent. (21) 
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4.3 Suitable scaffold material ELR as an alternative for fibrin-gel 
There are a lot of different materials used in tissue engineering. In this thesis the two 
hydrogels fibrin and elastin recombinamers were tested as scaffold. Those scaffolds were 
chosen because of their biocompatibility, easy molding ability and elasticity. For the BioStent 
the scaffolds have to prove the ability for endothelialization and the endothelial cells have to 
resist flow conditions. This will be tested by bioreactor conditioning. Besides cell 
compatibility, the mechanical requirements for coating need to be confirmed. To verify this, 
the scaffolds are used to cover the stents and are crimped and released. The gels need to 
provide a thin coverage and no damage during crimping. Fibrinogen was already used for 
several stents so the ability for endothelialization is already shown in chapter 4.1.2 and the 
ability for molding and crimping in chapter 4.2.1. Here the analysis for elastin-like 
recombinamers is shown as an alternative. 
 
4.3.1 Elastin-like recombinamers as an alternative for fibrin-gels 
Fibrin-gel is a very suitable material for tissue engineering, nevertheless as one of the major 
adhesion proteins it has also disadvantages with regard to unspecific protein and cell 
adhesion. One alternative material is elastin-like recombinamers (ELR). The ELR can be 
combined with different adhesion groups. So we tested three different ELR-gels for stent 
coating and conditioning. Tested adhesion groups were the EC specific REDV, the cell 
adhesion group RGD and the non-specific REDV as control.  
In static condition the cell cultivation on the different gels was tested. For control, the cells 
were grown on gelatin and the negative control was supplied without FCS. The cell amount 
was quantified using a life and dead staining. The living cells are stained in green and using a 
fluorescence plate reader the intensity was measured. By comparing the intensity to a 
standard curve, the amount of cells was calculated. The results are shown in figure 57.  
The cells growing on RGD show the highest amount of living cells where the VKV gels have 
the lowest cell number. The cells on the RGD and REDV are all growing well, also the RGD 
gels support the growth more than the others. 
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Figure 57: Proliferation of human endothelial cells on ELR gels after 1, 5, and 9 days of 
static cultivation (n=3). Gels with different adhesion groups VKV, RGD and REDV were 
tested (* P < 0.05, ** P < 0.001). Reprinted from Acta Biomaterialia, Israel González de 
Torre, Frederic Wolf, Mercedes Santos, Lisanne Rongen, Matilde Alonso, Stefan 
Jockenhoevel, José C. Rodríguez-Cabello, Petra Mela, Elastin-like recombinamer-covered 
stents: Towards a fully biocompatible and non-thrombogenic device for cardiovascular 
diseases (2014), with permission from Elsevier. 
 
After the static test, three stents were tested with RGD, REDV or both RGD+REDV gels. In the 
cell adhesion and growth on the fluid conditioned stents there is a higher difference seen 
between the stents. Figure 58 shows a staining of the lumen of the stents with life (green) 
and dead (red) staining. There is a much higher number of living cells seen on the RGD stent 
after flow conditioning.  
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REDV-gel RGD-REDV-gel RGD-gel 
 
Figure 58: ELR covered stent with different adhesion groups for endothelialization. The 
different adhesion groups REDV and RGD and a combination of both were tested for 
endothelialization and bioreactor conditioning under flow. After conditioning in the 
bioreactor under flow, the cells were stained. Green color indicates living cells, red dead 
cells. The gel gives a red background color itself.  
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4.4 Proof of function in vitro 
The hemocompatibility was tested in a chandler loop system with human blood. For analysis 
specific platelet staining (CD41/61) and SEM imaging was performed.  
 
4.4.1 Platelet adhesion on ovine stents in a Chandler loop-system  
The blood compatibility of the BioStent was proven by using a Chandler loop-system. In this 
experiment the stents were flushed with human blood for 1 h and afterwards analyzed by 
SEM and staining against CD41/61, a platelet antibody. For control a Gore-Tex® prosthesis 
was used. 
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Figure 59: Scanning electron microscopy (SEM) images after blood test in chandler loop 
system. Gore-Tex® served as control. Two tissue engineered stents were tested: one with 
damaged coating and one with full endothelial coating. The surface images show deposits 
after blood contact like erythrocytes and thrombocytes. 
 
As can be seen in the SEM imaging (figure 59), there is a high platelet adhesion on the Gore-
Tex® but nearly no platelets at the stents. This is also proven by the CD41/61 staining as 
marker of platelet activation. In figure 60, the positive staining against CD41/61 is visualized 
in green. The Gore-Tex® shows a lot of green fluorescent dots on the surface. The BioStent 
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without endothelial cells also shows green fluorescence. The stent with endothelial cells 
indicates nearly no positive staining. At the crimped stent the amount is higher than in the 
non-crimped one, but still much less compared to the non endothelialized stent.  
 
Gore-Tex® BioStent without EC 
 
BioStent with EC BioStent with EC after crimping 
 
Figure 60: Tissue engineered BioStent after blood contact in a Chandler loop. Staining 
against the thrombocyte marker CD41/CD61 (green) and DAPI (blue). A Gore-Tex® 
prosthesis served as control. The BioStent is shown under different conditions: without 
endothelial cells (EC), with EC and after crimping and release. Scale bars indicate 100µm. 
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4.5 Proof of function in vivo 
As final proof of function, the implantation in healthy sheep was addressed. After three 
months of implantation, a patent and still endothelialized stent without thrombosis was 
expected. For proof, the stents were implanted inside carotids in first place and as an 
interponate in further experiments. The patency during implantation time was controlled by 
ultrasonography and with angiography. After explantation the stents were analyzed using 
specific cell staining, SEM imaging and quantitative real time PCR. 
 
Pilot implantation study - intervascular 
In the first three animals, the nitinol stent Tricot 7 was used coated with myofibroblasts and 
fibrin-gel and lined with endothelial cells. The stent was crimped by a funnel into a 12 F 
(diameter of 4 mm, length of 15cm) catheter. Using a pusher, the stent was placed into the 
vessel. After deployment of the stent, angiography showed good arterial flow through the 
stent (figure 61).  
 
 
 
Figure 61: Angiography right after BioStent placement in sheep. 
 
When the stents were explanted, all three stents occluded due to thrombosis. In figure 62 
images of the three stents are shown. BioStent I deformed whereas BioStent II and III 
remained the round shape. Below the macroscopic pictures SEM images of the clot are 
shown.  
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Figure 62: Results BioStent experiments of the first animal trials. On top, pictures of the 
stent right after explantation and below scanning electron microscopy (SEM) images of the 
plaque inside the stent. 
 
Main iplantation study - interponate 
Due to these unfavorable results from the first three implantations the stents were 
implanted as interponate in the following 5 sheep. Therefore a piece of carotid artery was 
explanted and the stent was fixed by stitching with vascufil 6-0 suture material. The figure 63 
shows the schematic explanation of the surgical procedure. The transition of the stent and 
native artery was smooth, and after three weeks the stent was completely integrated. 
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Figure 63: Implantation of the BioStent as interponate. Top right after implantation in 
sheep, down: after three months of implantation. 
 
4.5.1 Ultrasound  
To examine the patency of the stents, ultrasound was performed every two weeks. 
Transaxial and longitudinal section images are shown in figure 64. The stent can be identified 
as the brighter structure than the native vessel wall. The images of stent 3 showed no flow 
signal as the stent occluded. Beside this, the other stents were patent. Stent 5 showed 
turbulence flow inside indicated by blue and red color, indicating stenosis of the stent edge.  
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Figure 64: Ultrasound images in transaxial and longitudinal direction of BioStents 
implanted in sheep. The flow direction is visualized by color. A Doppler ultrasound device 
was used. 
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4.5.2 Angiography 
The patency of the stent was proven by angiography after three months of implantation. In 
figure 65 the angiography images of all five sheep are shown. On the left side the image 
shows the stent position without contrast agent and on the right side with contrast agent. A 
red square denotes the part where the stent is positioned. Besides stent 3, all stents were 
patent. In stent 3 the contrast agent and so the blood cannot pass the stent but through a 
side branch next to the stent.  
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Figure 65: Angiography of the BioStents after three months of implantation in sheep. The 
left column shows the stent position without contrast agent the right column shows the 
same position with contrast agent. From top to bottom the sheep one to five are shown. 
The red squares denote the stent position. 
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4.5.3 Optical inspection of the stents and surfaces 
In total five sheep were used for stent implantation as interponate and four remained patent 
over the estimated three months. In figure 66 the inner surface of two stents are shown 
exemplarily. As can be seen there was no occlusion and a smooth bridge to the native tissue 
was grown.  
 
 
 
Figure 66: Example of BioStent as an interponate in sheep after three months of 
implantation. 
 
4.5.4 Tissue thickening 
The tissue thickening was measured on the cross section at three representable positions of 
the stents. As described in the setup for each sheep, two stents were prepared. The better 
stent was chosen for implantation and the second stent was used as in vitro control for 
comparison. The tissue thickening was measured for all stents (figure 67). The mean value of 
the in vitro samples and the in vivo samples were calculated and are visualized in figure 68. 
The values of in vitro 1 were not used because the measurement was not possible. Also the 
in vitro 5 values were not used for the calculation as an aberration with an unusual thick 
layer it is not representable for the pre operation status. The occluded stent in vivo 3 also 
was not measured because there is no lumen detectable.  
The calculated mean values resulted in a lower mean value in the in vitro samples compared 
to the in vivo samples. The calculated p-value is 0.15 and a significant increasement by 
41.7 % was detected. 
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Figure 67: Cross sections of in vitro and in vivo stents stained with H&E. Squares show 
position for tissue thickening measurement. 
 
Figure 68: Mean tissue thickness on in vitro and in vivo stents. Tissue between stent 
surface and lumen was measured. 
 
4.5.5 Histology 
To analyze the tissue formation, slides of the stents were stained with hematoxylin and 
eosin. For each animal one stent was analyzed after in vitro cultivation. Figure 69 shows an 
example of one stent after three weeks of cultivation in the bioreactor. A thin tissue layer 
surrounded the stent. In the closer view the cytoplasm in red and the nuclei in blue can be 
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seen. The tissue formation was stronger on the surface where the nutrients are available 
easier. 
 
 
Figure 69: In vitro BioStent example of BioStent 4, overview and closer magnifications 
stained with H&E. Scale bars indicate 1000 µm (left), 100 µm (middle) and 50 µm (right). 
 
After implantation the stents are analyzed with HE-staining as well. As can be seen in figure 
70 the tissue formation did increase over time of implantation. At the surface the structure 
is denser except for stent 3 which was closed. Here, the inner part of the stent was more 
porous.  
 
In vivo 1 In vivo 2 In vivo 3 
 
In vivo 4 In vivo 5 Carotid 
 
 
Figure 70: H&E staining of the five BioStents after implantation and a non-treated carotid 
as control. Scale bars indicate 100 µm. 
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4.5.6 Immunohistochemistry 
To analyze not only the structure of the tissue, but also the specificity of the cells, specific 
antibody stainings were completed. In one step, the slices were stained against αSMA (red) 
and collagen I (green), as can be seen in figure 70 for one in vitro stent and in figure 71 for 
the in vivo stents. In the in vitro example the thin tissue layer already contains αSMA and 
some collagen I. After in vivo cultivation the tissue did change and a lot more collagen I can 
be detected.  
 
 
 
Figure 71: Example of in vitro BioStent cross section. Results with αSMA (red) and collagen 
1 (green) staining. Cell nuclei were stained with DAPI in blue. Scale bars indicate 200 µm 
(left), 100 µm (middle) and 50 µm (right).  
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Figure 72: In vivo BioStent cross section results with αSMA (red) and collagen 1 (green) 
staining. Cell nuclei were stained with DAPI in blue. An ovine carotid served as control. 
Scale bars indicate 100 µm. 
 
The EC lining was proven by the EC specific antibody von Willebrand factor, shown in figure 
73 and figure 74 in green. 
 
 
Figure 73: In vitro BioStent cross section results with vWF staining (green). Cell nuclei were 
stained with DAPI in blue. Scale bars indicate 200 µm (left), 100 µm (middle) and 50 µm 
(right). 
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Figure 74: In vivo BioStent cross section results with vWF staining (green). Cell nuclei were 
stained with DAPI in blue. An ovine carotid served as control. Scale bars indicate 50 µm. 
 
4.5.7 Scanning electron microscopy 
With the scanning electron microscopy very high magnifications are possible and the surface 
of the stent can be visualized. In figure 75 an overview of the implanted stents is shown. To 
give an impression of a bigger part of the stent several images were stitched together using a 
photo process program (Hugin, version 2011.2.0.3, http://hugin.sourceforge.net/). Except 
for the occluded stent 3 a smooth surface was shown.  
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Figure 75: Overview stitched scanning electron microscopy (SEM) images of BioStents in 
vivo 1-5. 
 
The luminal side of the stent showed the cell formation and structure. In figure 76, as an 
example, the inner surface of a native carotid is shown. The artery surface shows a 
homogeneous surface with cells orient to the blood flow.  
 
Magnification (scale bar 200 µm) Magnification (scale bar 50 µm) 
 
 
Figure 76: Native carotid surface in scanning electron microscope. 
 
From all stents SEM images have been made. Including both stents prepared for each sheep 
the one implanted (in vivo stent) and the one which was not implanted and serves now as 
control for the status prior to implantation (in vitro stent). An overview of the five not 
implanted stents (in vitro stents) is given in figure 77. An overview of the five in vivo stents is 
       1  2   3  4  5 
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shown below in figure 78. The in vitro stents showed a smooth surface with a confluent cell 
layer. As can be seen, the orientation was not homogeneous and the cell formation also 
varies between the different stents. The cell growth in the in vitro stents was more 
orientated except for stent 1, which shows more flatten cells and not very dense cell growth. 
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Figure 77: Overview scanning electron microscopy (SEM) images of in vitro BioStent lumen 
as status before implantation. 
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Figure 78: Overview scanning electron microscopy (SEM) images of in vivo BioStent lumen 
after three months of implantation in sheep.  
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4.5.8 qPCR 
For analysis of the endothelial cells on gene level a qPCR for the marker CD31, vWF, eNOS 
and KDR was performed. The expression rate was normalized to the house keeping gene 
β-Actin. The results were correlated to one carotid. 
 
 
 
Figure 79: qPCR results of in vivo study II. The gene expression of CD31, vWF, eNOS and 
KDR are shown for the cell culture sample the in vitro and in vivo samples compared to a 
native carotid. * indicate significance. 
 
Figure 79 visualizes the expression rate for CD31, vWF and eNOS. There was a decrease in 
cell culture and in vitro cultivaton detected. After implantation the expression rate increased 
again, although there was a high variance between sheep. KDR (VEGFR-2) was much higher 
expressed in cell culture. The in vitro expression was nearly zero and increased in vivo again. 
Data were expressed as the mean ± standard error. The statistical significance was 
determined using the Student’s t test. Differences were considered to be statistically 
significant at p < 0.05. 
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5 Discussion 
The research on atherosclerosis therapy is ongoing for decades. This thesis is focused on 
lesions where interventional treatment is required with special focus on stents. For care of 
late stage atherosclerosis two things are of high importance; first to exclude the diseased 
tissue and second to renew a healthy surface of endothelial cells. Nowadays, there is no 
treatment, except for vessel replacement, which guarantees those issues. Addressing those 
issues, in this study a tissue covered and endothelialized stent was used. Literature revealed 
the possibility to use covered stents to support the treated vessel and also exclude the 
injured atheromatous plaque(15). Nevertheless, a randomized trial comparing synthetic 
covered stents with bare metal stents revealed better short and long term outcomes for 
bare metal stents(15). Although, the coverage can be supplied by antithrombotics like 
heparin, this does not compensate the endothelial layer. An in vivo endothelialization, 
especially for long stents, is questionable because of limited reendothelialization from the 
anastomosis(11) and limitations in reendothelialization by floating EPC(24, 36, 37) as well. 
The endothelial cell layer is elementary for vascular healing. Endothelialization was already 
done on vascular grafts(89, 90). In this study, the two above-mentioned original technologies 
of a covered stent and in vitro endothelialization were combined.  
An impact on vessel healing, reduction of intima thickening and reduced restenosis by 
endothelial coverage was already proven(43, 44). Therefore the focus of this study lies on 
the endothelial cells. For a good cell attachment the environment is very important(28). The 
best way is to mimic the natural circumstances as close as possible. A fibrin-gel was used for 
coverage, exhibiting best conditions for tissue engineering. As one part of the coagulation 
cascade, fibrinogen is the ideal source for vessel healing and furthermore easy to isolate out 
of the patient’s blood(91). As previously shown, combined with smooth muscle cells and 
fibroblasts, the cells create extracellular matrix and tissue formation occurs over time(82). 
To stimulate the ECM production the stents were cultured in a pulsatile flow bioreactor 
system. The ECs showed a good attachment on the natural surface. As second matrix, 
elastin-like recombinamers were tested as scaffold as well, with good attachment when 
linked with RGD.  
Cells for the tissue engineered stent can be harvested from a biopsy of blood vessel. As 
already described in literature, the connection of SMC and EC is highly interesting. A 
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damaged endothelial layer increases the cell proliferation of vascular smooth muscle cells, 
localized near by the injury(92). In healthy tissue, the production of TGF-β1 can inhibit the 
SMC proliferation and stimulate the ECM synthesis(93). Apart from the suitable cells to use 
and the right environment to let them grow, the performance has to be shown. This is what 
was done within a first animal trial. After earlier animal trials within sheep, where a tissue–
engineered vessel was implanted successfully, the results for the stent were expected to be 
promising(89). Nevertheless, a stent is quiet more challenging. For instance, the coating 
must be very thin for placement inside the vessel. Last but not least, the problem of crimping 
has to be addressed. The challenges can be handled. The stent structure chosen could be 
coated with a thin layer of tissue (~300-400 µm) and could be crimped as shown before(82). 
Another problem is a limited radial force because of which the stent could not be implanted 
by catheter. However, focusing in the tissue coverage the stent was implanted surgically. Still 
the question remains if after crimping there might be an activation of the endothelial cells 
causing an early stenosis. The animal trial proved a success in four of five experiments.  
 
5.1 Evaluation of sources of endothelial cells 
In this thesis two cell types were tested as cell source, endothelial progenitor cells (EPC) 
isolated out of blood and endothelial cells (EC) out of blood vessels. The suitability for 
biologized implants like the BioStent was tested in regard to cell harvesting and cultivation, 
transdifferentiation, molding and conditioning. For the BioStent the vascular EC were 
detected as most suitable.  
Particularly with regard to the clinical translation, the harvesting of EPC out of a blood 
sample is much easier than to explant a sufficient blood vessel from the patient. 
Nevertheless the EPCs still have to differentiate into ECs. In either case high amounts of cells 
are needed. For EPCs the passaging is quiet difficult and a high cell number needs to be 
isolated right from the beginning. 
For the BioStent coverage 2x10
7 
EPC/ml were used. The preseeded staining with Ac-DiI-LDL 
proved the cell adhesion and coverage also after flow conditioning. But still with such high 
initial cell number no smooth and confluent coverage could be achieved. Although the group 
of Matsuda, showed a nice endothelialization using canine EPC for stent(48) and vascular(94) 
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seeding after 7 days of cultivation, those results using human EPC could not be affirmed 
within this study. A comprehensive analysis of EPC under shear stress showed a loss of 
function and insufficient ability for the use in tissue engineering(37) as well. 
Furthermore, the number and quality of EPC differs hugely by the patient dependent on the 
age(35) and disease pattern. Werner et al. found a correlation between the number of 
circulating EPC and death from cardiovascular causes, indicating a correlation between low 
EPC numbers and higher cardiovascular death rates(95). Those personal variations make EPC 
an unreliable cell source. Although the results in preclinical studies(49, 94, 96) are promising 
the translation into clinic is questionable considering the use of patient derived EPC. 
Using adult EC from blood vessels provides already differentiated cells. Usually only a small 
piece of vessel is available for harvesting, therefore cell expansion in vitro is necessary. For 
successful cell expansion the initial cell number of growing cells and the stable cultivation 
without transdifferentiation are important. To improve the yield of cells two mediums were 
tested. Comparing endothelial cell medium from Lonza to the endothelial medium from PAA, 
the results showed better cell growth and higher colony number after isolation in medium of 
Lonza (chapter 4.1.3). The staining against von Willebrand factor (vWF) showed no 
difference in regard to the used medium. The cell output was mainly affected by the donor 
itself. This is an effect expected in clinic as well(35).  
The cultivation of cells over several passages already showed an increased risk of 
transdifferentiation and leakage of typical markers and function(97),(98),(99). The analysis of 
three different human endothelial cell lines over ten passages showed a change in cell 
morphology and protein expression. Already after passage four a shift in cell morphology 
was detected (figure 38). Additionally, expression levels of endothelial proteins (CD31, vWF, 
KDR and eNOS) were examined on translational and transcriptional level. 
On translational level the proteins CD31, KDR and eNOS were examined using FACS analysis. 
Not considered was vWF, as an epitope inside the cell. For analysis of epitopes inside the cell 
a permeabilization is needed, during which a lot of cells get lost, which was no option in case 
of the small cell samples used.  
For FACS analysis the gate was defined using cells in passage zero. The analysis over ten 
passages showed no difference in the CD31 expression. Inside the defined gate nearly 100 % 
of cells were positive. The expression of KDR (also known as vascular endothelial growth 
factor receptor-2: VEGFR-2) instead showed a drastic drop right after the first passage, after 
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passage six in one cell line the expression rose again. The low expression is surprising, 
because the proliferation is, amongst others, regulated by KDR. The expression of eNOS was, 
except for one outliner, always lower than 3 %, which might be due to the missing shear 
stress during cell culture. Concluding, a homogeneous outcome was observed for cells inside 
the gate, with about 100 % CD31 positive cells and very little KDR and eNOS positive cells.  
The analysis on transcriptional level, using qPCR, showed quiet heterogenic outcomes for the 
three cell lines. For CD31, a tendency to lose the expression can be seen, but there was an 
increase in cell line one until passage six. For KDR, vWF and eNOS the expression ratio varies 
drastically between the three cell lines. No trend can be detected in regard to increase or 
decrease of the expression ratio.  
Taken together, these results show a change in cell morphology and gene expression. The 
homogeneous results of the FACS analysis are misleading. By only measuring the gated cells 
only the cells of the original phenotype were considered. In the qPCR the total cell culture 
was measured instead, resulting in total heterogenic outcomes in expression. This shows an 
inhomogeneous change in expression which can be correlated to the morphological 
changes. Showing that the CD31 expression of the gated cells remained constant, it is 
possible to sort the cells by their phenotype like size and granularity. The low expression of 
eNOS and KDR might be due to a fastened down regulation. 
A morphological change in senescent HUVECs was already observed previously by 
Hampel(98) and Unterluggauer(99). The group of Seifalian published results about HUVEC 
cultivation over 12 passages, without significant changes for the markers TGFI3-1, collagen-1 
and PECAM-1 (CD31)(100). These controversial results might be due to the low duplication 
rate compared to the results of Hampel and Unterluggauer and the results shown here. 
For endothelialization on the BioStent ECs in passage four were used. In a rotational process 
4*10
6
 cells/ml were seeded for over six hours with additional bioreactor conditioning. After 
4, 6 and 8 days of conditioning the confluences were proven by SEM imaging (figure 35). The 
images proved a confluent EC layer after 6 days. For further experiments an appropriate 
conditioning time of seven days was used. 
In conclusion the endothelial cells from the blood vessel are more difficult to harvest and 
need an open surgery, but used in an early passage they form a homogeneous smooth 
surface on the stent after one week of cultivation. Whereas the EPCs can be isolated easily, 
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but are difficult to cultivate and therefore high amounts have to be isolated. Furthermore, 
they failed in the coverage for the BioStent by not forming a smooth surface.  
Diseased people frequently lack appropriate vessels for EC harvesting. Besides EC and EPC 
there are also other options for vascular coverage.  
EC extraction is also possible out of fat like omental fat, subcutaneous fat, pericardial fat or 
mediastinal fat(101). EC from fat are easy to extract and available in high numbers, making a 
single-stage-seeding possible(90). Usual methods for extraction are filtration, Percoll 
extraction or magnetic bead separation (Dynabeat). Those methods harbor a high risk of 
contamination. Additionally,  extraction by Percoll or filtration significantly reduce the 
number of EC extracted(90).  
Fat derived endothelial cells are an alternative especially for single-stage-seeding but a 
general trend can be seen towards adipose stem cells (ASC). Policha et al. (102) found that 
also ASC from diabetic patients are suitable for treatment. The results for isolation and 
proliferation suggest adipose stem cells as a promising source for tissue engineering in the 
diabetic and non-diabetic population(102). Unlike EC and EPC the ASC is not limited in 
number and function in elderly patients with vascular disease (102). 
Besides ASC, mesenchymal stem cells are another option. Hibino et al.(103) seeded grafts 
with bone marrow derived mononuclear cells as venous conduits for congenital heart 
surgery in human. There was no evidence for graft- related mortality or stenosis after a 
mean follow-up of 5.8 years(104). Nevertheless, the risk of unsuccessful differentiation of 
adult stem cells and difficulties in upscaling remain a significant hurdle(105).  
Another option are induced pluripotent stem cells (iPSC). The precursor cells for iPSCs could 
be obtained from patients easily. The iPSC have the potential for creating a pluripotent cell 
line from a patient’s own somatic cells(104). Hibino et al. used a iPSC sheet to construct a 
tissue engineered vascular graft in mice.  No thrombosis, aneurysm formation, graft rupture 
or calcification was detected(103).  
Concluding, there are a lot of options of cell sources for endothelialization. The right source 
hugely depends on the patient itself and the method used for endothelialization. First the 
availability of cells has to be proven for the specific patient, then the seeding method needs 
to be considered. For example, cells requiring a long cultivation time are not usable for 
single-stage-seeding.  
 
Discussion 
143 
 
5.2 Usability of stent design and properties for tissue covered stents 
Knitted stent structures out of nitinol were evaluated as promising stent structure. 
Nevertheless improvement on the mechanical forces is needed. 
It is an elementary aim to create a functional composite of the stent structure and tissue 
coverage. Not every stent structure is usable for vitalization. Balloon dilatable stents would 
damage the endothelial lining, therefore only self-expandable stents were considered. The 
most common material for self-expandable stents is nitinol. In this thesis different knitted 
and wired structures were tested. In a first try a full nitinol warp knitted stent and two 
composites of nitinol and PVDF were tested. The composite of Nitinol and PVDF failed during 
cultivation and crimping (chapter 4.2). The different material properties lead to deformation 
during tissue cultivation. Furthermore the tissue ripped during crimping. 
Therefore the focus was set on nitinol stents without PVDF support. In a next step warp 
knitted structures and braided structures with different mesh density were tested. During 
cultivation the braided stents deform drastically. Therefore the stents were fixed at the 
edges during cultivation, leading to reduced deformation. During crimping the stent struts of 
the braided stents deform inhomogeneously and destroyed the tissue. Two different 
methods for crimping (by funnel and by squeezing) were used, but both failed due to strong 
tissue damage. The warp knitted stent was easy to cultivate also without fixation at the 
edges and could be crimped with funnel and tubing system. Because the warp knitted stent 
contains a lot of nitinol struts, as well as overlapping struts, the structure is very dense with 
a high wall thickness. The braided stents are less dense and thick but failed during tissue 
cultivation and crimping. As a consequence the 3D stent, a braided stent with a longitudinal 
supporting wire was tested. This stent proved its ability for cultivation with tissue and also 
convinced during crimping. The crimping process with a tubing system, where the pressure 
was applied homogeneously from the outside, was usable. Without a commercial crimping 
device this was only an option for very small samples less than 2 cm. The warp knitted stent 
could also be crimped by funnel, which enables for crimping stents of 4 cm length.  
Concluding, the composite-stent and the braided stents failed during cultivation and 
crimping. The warp knitted stent and the 3D braided stent are both usable for the BioStent 
application. The 3D stent is promising, because of less stent material and thinner walls. 
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Nevertheless, because of the easier crimping method the warp knitted stent was chosen for 
further experiments. 
The warp knitted stent was mechanically characterized and by changing the mesh density 
and the binding additional structures were tested for comparison to find the ideal stent 
structure. At the ITA four different stent types were produced (tricot 7, tricot 10, 
charmeuse 5 and charmeuse 7) and analyzed mechanically(21). The results showed an 
increase in radial force at increasing mesh density from tricot 7 to tricot 10 and also at 
increasing underlap from tricot 7 to charmeuse 7. Also the bending stiffness is increased by 
higher mesh density. In comparison to tricot the bending stiffness is lower in charmeuse 
stents. 
For the BioStent a high radial resistance by low bending stiffness is required. The mechanical 
analysis resulted in the awareness, that the used tricot 7 stent has the worst mechanical 
requirements. In regard to the radial force, tricot 10 is the most promising stent for 
application. Nevertheless, all stents failed in comparison to commercial stent data. 
Commercially available stents reach at least a radial force of 4.94 cN/mm (106), whereas the 
tricot 10 reached only 4.78 cN/mm. In regard to the bending stiffness the tricot 10 shows 
instead the highest stiffness of 596.09 Nmm
2
, which is not desirable, especially in the 
peripheral arteries. Commercial stents have a bending stiffness between 6.08 – 70.1 Nmm
2
, 
according to the analysis of Schmidt(106). In conclusion the radial force could be enhanced 
by mesh density increase and by increased underlap, like charmeuse. Charmeuse could also 
convince in bending stiffness. Taking together, Charmeuse 5, with low bending stiffness 
(90.19 Nmm
2
) and increased radial force (2.85 cN/mm), shows the most promising results 
for the BioStent. However the mechanical properties of commercial stents could still not be 
achieved.  
To analyze the capability for use in tissue engineering, tricot 10 and charmeuse 5 were 
molded and cultivated. Both stents could be molded without difficulties or deformation 
during conditioning. The surface analysis using SEM imaging showed a smoother surface for 
the tricot 10 compared to the charmeuse 5. The loose structure of the charmeuse 5 stent 
showed loops of the mesh which were not correctly integrated in the scaffold. Therefore, 
the coverage with tissue was not as homogeneous as needed. Although, the results of 
mechanical testing were promising, a better stent structure needs to be found. It has to be 
analyzed if the stent fabrication can be optimized for a homogeneous production. 
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Furthermore, the mechanical properties would still benefit of improvement. If the 
mechanical properties cannot be improved sufficiently also other stent structures should be 
considered. Nakajama et al. produced a tissue covered stent as well(25). Although the tissue 
formation is different and there are no EC on the surface it is possible to crimp and release 
the stent without relevant tissue damage. In 2014 first in vivo experiments could prove the 
application in beagles(45). Nevertheless, because of the missing EC-layer a balloon-
expandable stent made of stainless steel (Goodman, Aichi, Japan) could be used in this trial. 
 
5.3 Suitable scaffold material ELR as an alternative for fibrin-gel 
Two hydrogels were tested for coating fibrin-gel and elastin-like recombinamers. Fibrin 
proved to be a suitable material for the BioStent also in the animal trials. The in vitro 
experiments on ELR-gels showed better mechanical strength and reduced incubation time. 
Therefore in future ELR-gels seem to be the material of choice. 
Nevertheless, fibrin-gel has a lot of good properties, namely it is easy to mold, autologous 
and biocompatible. Its weakness is the mechanical stability. Fibrin gels alone cannot 
withstand the blood pressure. Therefore included cells for tissue formation are required. 
Although those results are good, a long cultivation time for cell culture and conditioning is 
needed. Therefore no bedside application of a fibrin based tissue engineered stent is 
possible. To reduce the production time, a different hydrogel was tested for stent coverage, 
the elastin-like recombinamers (ELR). The mechanical strength of those hydrogels can be 
adjusted by their concentration. Additional specific functional groups can be attached, for 
example to increase EC adhesion or induce EPC adhesion from the blood flow. 
In a first step the endothelial cell adhesion on different functionalized ELR-gels was tested. 
The cells were seeded in static culture on gels without adhesion molecules (VKV-gels), with 
cell-adhesion molecules (RGD) or with EC-adhesion molecules (REDV). Without flow 
stimulation, the cells could grow on each gel. However, the endothelial proliferation was 
highest on the RGD-gels. On the REDV gels the cells still grow but the proliferation was 
slower. The cells on the VKV-gels proliferate slowest and almost halve as fast as on the RGD-
gels. In summary, it can be stated that the EC can grow on all the ELR-gels, however the 
attachment and growth on the RGD-functionalized gels is best. RGD is a cell-adhesion 
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domain which is nonspecific, in contrast to REDV which is specific to endothelial cells. 
Therefore REDV is more interesting for the BioStent because no other cells would be forced 
to bind on the stent. Unfortunately the flow experiments showed no sufficient results. The 
ELR covered and endothelialized stents showed nearly no endothelial cells on the REDV and 
on a combination of REDV and RGD stents. Only some cells could be detected next to the 
stent struts where the medium flow was not that strong. However, the RGD coated stents 
were very promising and showed a nice endothelial coverage. Concluding, the stents 
covered with elastin-like polymer gels, functionalized with RGD, are strong enough for direct 
endothelialization, without supporting cells inside the gel. Thus a time saving of around two 
months can be achieved. 
The field of used scaffolds for vascular tissue engineering is huge. There are polymeric 
scaffolds (Dacron, ePTFE), decellularized vascular scaffolds (xenograft, allograft), natural 
polymeric scaffolds (collagen, elastin, fibrin, hyaluronan, chitosan, gelatin, silk fibroin), 
degradable synthetic polymers (PGA, PLA, PCL PHA, PDS, PU, PGS), blends and composites. 
But not all are suitable for the BioStent. For large vessels polymeric scaffolds like Dacron and 
ePTFE are suitable materials but failed in vessels less than 6 mm diameter (107). Degradable 
synthetic polymers are suitable for smaller vessels but degradative products show elicit 
inflammatory response(107). Suitable scaffolds are natural scaffolds with low body reaction. 
An often used material is decellularized native tissue (28). Using decellularized scaffolds 
there is a risk of calcification, inflammatory responses and viral disease transmission 
probability if the process was not done carefully. Additionally, biomechanical changes due to 
the chemical and physical stress during decellularizaton may occur(33, 107). Natural 
polymers do not show chronic inflammation or toxicity in general(107). The  most often used 
natural polymeric scaffold is collagen(54–56, 58), first used by Weinberg-Bell in 1986(59). 
Collagen is one of the main ECM proteins with excellent cell-binding properties, outstanding 
tensile strength and incorporated growth factors like VEGF and FGF2. Because of low 
mechanical strength it was often used with a supporting scaffold like Dacron(108). 
Nevertheless, degradation products resulted in production of amino acids with 
thrombogenic potential (107). Additionally, using xenogeneic or allogeneic scaffolds, the risk 
of immunoreaction is enhanced (107). The addition of elastin to collagen gels lead to 
increased proliferation of EC and inhibition of SMC hyperplasia(109). Nevertheless, using 
animal derived elastin my cause immunoreactions resulting in aneurysmal graft failure (107).  
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Fibrin gels were used for tissue engineering as well. For example the group of Tranquillo 
changed from collagen(110) scaffolds to fibrinogen scaffolds(111). The advantage of fibrin 
gel is the ability to isolate the components fibrinogen and thrombin directly from patients’ 
blood(112) and circumvents immunoreaction. Nevertheless, fibrin localization poses an 
initiation of coagulation cascade (107). However, using endothelial cells for lining, this 
problem can be prevented. 
 
5.4 Proof of function in vitro 
The in vitro tests proved a healthy tissue formation, a thin coverage and prevention of 
thrombocyte adhesion. 
To simulate the blood flow, the stent was placed in a Chandler loop (figure 29). A Gore-Tex® 
prosthesis served as control. After one hour of blood contact the samples were analyzed by 
SEM to estimate thrombocyte adhesion, blood clotting and fibrin formation. On the Gore-
Tex® control, the images showed a high thrombocyte adhesion, as well as fibrin formation. 
The endothelialized stent samples instead, proved to inhibit the thrombocyte adhesion, 
further on no fibrin formation could be detected. Additional staining against the 
thrombocyte marker CD41/61 proved those results. There were only a few thrombocytes 
detected on the endothelialized surface. The direct comparison of a BioStent with and 
without EC showed an increased thrombocyte adhesion for the not endothelialized stent. 
This proved not only the function of the endothelial cell layer in the blood stream but also 
the necessity of the endothelialization. The platelet adhesion was already detectable after 
one hour of blood contact. Reendothelialization, if even possible, would last at least weeks. 
Because of limited migration of endothelial cells at the anastomosis (11) a pre-seeding is 
obligated. Although further tests regarding plasmatic activation should be done, those 
results indicate the great benefit of the endothelial cell layer.  
Approaches like the in vivo tissue engineered stent of Nakajama(25, 45) and the tissue 
coated stent of L’Heureux and Mc Allister(46) showed good results in animal trials as well, 
but without endothelial cells the translation into clinic is questionable. The blood tests using 
human endothelial cells indicated impressively the necessity of the endothelial surface.  
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Achneck et al. seeded titanium cardiovascular devices with EPC(50) prior implantation. In 
vivo results proved an increased hemocompatibility in endothlialized titanium Tubes(51). 
After 21 days of implantation in pigs the non-seeded tubes were completely occluded 
whereas the EPC covered tubes remained patent. This indicates an increased 
hemocompatibility achieved by EPC as well.  
Shirota et al. investigated a EPC inoculated hybrid tissue for stent therapy(49). He 
encapsulated canine peripheral EPC in collagen gel and mounted it on a metallic stent 
(diameter: 1.5 mm; length: 2 cm; a prototype stent supplied by Odensha, Kawasaki, Japan). 
After seven days in vitro culture in hybrid vascular medial tissue the EPC migrated towards 
the luminal surface.  
With those indications, as in the BioStent an endothelial layer will be achieved right at the 
implantation time. Nevertheless by using EPC high variance from patient to patient is 
expected and the translation into clinic has to prove the visibility. 
Besides preendothelialization EPC-capturing stents promise early reendothelialization as 
well. As already mentioned before, the quality and number of EPCs in the patient varies 
hugely. Especially elderly and diseased people might not have sufficient EPCs. Additionally, 
the capturing out of the blood flow and the ability to translate into EC is discussed 
controversially.  
To avoid the risk of EPC capturing Uthamaraj designed a novel ferromagnetic bare metal 
stent to capture magnetically-labeled endothelial cells right after stent placement(96). Three 
weeks before implantation the endothelial cells were isolated out of the patients’ blood and 
magnetically-labeled with SPION and CM-DiI. Right after stent placement the cells were 
injected immediately at the stent. The vessel is blocked with the wire balloon catheter for 
two min to allow adhesion. The animal trials verified endothelialization seven days after 
implantation. 
 
5.5 Proof of function in vivo 
BioStent implantation as interponate proved patent and still endothelialized stents without 
thrombosis in four of five sheep after three months of implanation.  
The first in vivo experiment, using the BioStent, was planned to insert the stent inside the 
carotid of healthy sheep. The preconditioned and endothelialized stents were crimped inside 
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a 12 F catheter and implanted under view. The stents were pushed inside the carotid and 
expanded autonomously. The immediate angiography proved blood flow through the stent. 
Unfortunately all three stents failed and closed within two weeks. After explantation a total 
occlusion got visible. The SEM imaging proved clotting with fibrin formation, thrombocytes 
and blood cells.  
Which was not considered is that the radial force of the stent was not sufficient to 
completely expand inside the vessel. The not completely expanded stent narrowed the 
blood vessel, leading via a induction of turbulences to an complete occlusion. By not fully 
expanding, the stent was undersized for the vessel. Chen at al. analyzed the effect of stent 
sizing as a potential mechanism for in stent restenosis(113). According to their results an 
undersized stent leads to low wall shear stress, combined with high spatial wall shear stress 
gradient, which may contribute to intima hyperplasia. The tissue coverage reduced the 
lumen even more, which worsened the situation. 
 
Realizing the mechanical problems of the stent, the animal trial was adapted to achieve 
results regarding the stent coverage, in the in vivo study by implanting the stent as an 
interponate. 
After 3 months, four out five ovine stents were patent showing positive remodeling and no 
evidence of thrombus, calcification, or aneurysm formation. 
Prior to implantation the stents were crimped and released to simulate the crimping 
process. Instead of release inside the limiting lumen of the blood vessel the stents were 
expanded in vitro. Afterwards the stents were implanted serially connected to the carotid. 
During implantation time the sheep were monitored by regular ultrasound examination. At 
explantation time a final ultrasonography and angiography were performed. The ultrasound 
examination proved patency and blood flow in four of five sheep. It can be estimated that 
the flow was homogeneous in the stents except for stent five, where some turbulences were 
detected. At explantation time a completing angiography was performed visualizing the 
blood flow contrast agent. Except for the blocked vessel no stenosis was detected. At the 
anastomosis of one stent a slight necking can be seen. As shown in the ultrasound images 
this led only to slight turbulent flow in stent 5.  
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Most stents showed a smooth surface, without thrombocyte adhesion on the stent after 
explantation. Only at the anastomosis thrombocytes were detected where the stent was 
fixed by suturing. Usually there would not be any stitching using a regular stent implantation 
method. Nevertheless, the bridge between stent and tissue would have to be analyzed 
under regular conditions, namely inside the vessel. The four stents proved the ability to be 
crimped and released without damage of the tissue or endothelial cell activation. The thin 
tissue coverage could withstand the blood flow, even after crimping. The absence of 
thrombocyte adhesion on the surface proved the endothelial function.  
From each sheep, the not implanted control stent (in vitro stent) and the implanted stent (in 
vivo stent), slices were prepared. In the cross-sections the tissue thickening was compared. 
The distance from the innermost stent strut to the lumen surface was measured. The values 
of the in vitro stents were 0.219 mm whereas the in vivo samples measured in mean 
0.310 mm. This means a thickening of 0.091 mm (41.7 %). By assuming a lumen of originally 
5.5 mm (Inner cylinder), a thickening of 0.182 mm, results in a lumen loss of 3.3 %.  
According to several study’s reviewed by Chaabane et al., the late intima loss after stenting 
varies from 0.01 – 0.93 mm in DES and from 0.44 – 1.05 mm in BMS(114). With a lumen loss 
of 0.182 mm the BioStent results are much better compared to the BMS and even localized 
in the top results of the DES.  
Nakayama predicates “The ideal tissue for the blood-contacting luminal surface, is a 
completely endothelialized tissue prior to implantation”(25). Analogously, the endothelial 
lining of the stent surface, is most important for the BioStent concept. For surface analysis, 
scanning electron microscopy (SEM) was used. The specific cell detection was done by 
immunohistology on the cross sections. The SEM images of the in vitro and in vivo stent 
pieces show endothelial like cells on the surface. In all stent the cells were oriented to the 
flow. In the in vitro results the cells were not oriented longitudinal to the stent due to 
turbulent flow conditions. Instead, in the in vivo results a nice pattern of cells oriented 
longitudinal to the stent was detected. The morphology of the surface cells conforms to the 
EC morphology. Nevertheless, a specific staining against vWF was done to prove the 
endothelial layer. In cross sections of PMMA embedded stents a monolayer of endothelial 
cells was proven. Caused by the thickness of the PMMA slices the EC-layer appears blurry in 
some images.  
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The markers vWF, eNOS, KDR (VEGFR-2) and CD31 (PECAM-1) were analyzed on 
transcriptional level using qPCR. For each sheep samples of the EC culture at seeding time, in 
vitro stent and in vivo stent were taken and compared to freshly taken ECs from a sheep 
carotid. In cell culture a reduction in expression of vWF, eNOS and CD31 was detected, 
although the staining against vWF in cell culture was positive. The decrease of CD31 was 
expected, because the expression ratio of CD31 is down-regulated without mechanical 
stimuli (115). Also highly activated by blood flow and the subsequent shear stress, eNOS was 
down-regulated as well. Under static conditions it is known that the mRNA level of eNOS is 
rapidly decreasing(70). The expression of KDR was increased during the high proliferating 
cell culture. This was expected since KDR is involved in proliferation and angiogenesis(79, 
80). After conditioning in the bioreactor system, the expression increased. This might be due 
to confluency, inhibiting the proliferation. In vivo the expression increased a bit but not as 
much as in cell culture.  
During in vitro cultivation, in the bioreactor, an increase in shear stress related genes was 
expected. Nevertheless, the results disprove this assumption. The shear stress in the 
bioreactor system is with 0.16 Pa only 10% of the mean shear stress in blood vessels(87) and 
therefore too low for cell stimulation.  
However, in vivo the expression of CD31, vWF and eNOS did increase. One main aspect for 
this is supposedly the higher shear rates in native conditions which increased the expression 
for CD31 and eNOS. Also the expression was stopped during cell culture the potential was 
still there and was activated after implantation.  
One of the five implanted stents closed within the first two weeks. The angiography showed 
the outgrowth of a lateral blood vessel, compensating the blockade. In the SEM images 
fibrinogen deposits were detected. The HE-staining showed a thickening of tissue formation. 
Also the immunohistology proved cell distribution through the plaque, stained with DAPI. 
There were no ECs detected, but a high density of collagen I and local αSMA distribution was 
detected. This leads to the conclusion of an in stent restenosis. A possible cause might be a 
rupture of the stent coverage, activating endothelial cells which lead to increased intima 
thickening(28). 
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An autologous stent coverage was already addressed earlier by Nakayama et al.(25). He 
implanted a stent on a tube subcutaneously in rabbits. A tissue formation has grown on the 
stent after one month. The stent proved to be crimped without relevant damage. Although 
Nakayama commits the endothelial layer prior to implantation would be ideal, it was not 
possible to endothelialize the in vivo covered stent prior to implantation.  
An implantation study in beagles was performed over one month. The stents were covered 
using the in-body tissue architecture in one beagle for 4 weeks and implanted afterwards as 
an allograft into another beagle for one month. The results showed neither stenosis and 
aneurysm changes nor thrombus formation. A neointima formation on the whole stent was 
achieved. Although, there was no pre-seeding with endothelial cells the H&E staining 
showed some cells on the surface(45).  
The results proved the hemocompatibility of a tissue engineered self-expandable stent. 
Nevertheless, without the endothelial lining the most difficult component is missing here.  
To guarantee the complete tissue formation, Zilla et al.(34) used a healthy vein supported by 
a stent for vessel replacement. The combination of a vein graft with a stabilizing stent 
structure showed better long term outcomes compared to vein replacement alone. The 
biological conditions are very close to the BioStent. In each concept the stent is covered by 
autologous tissue with endothelial lining. Nevertheless, in case of the vein stent still an 
appropriate vessel needs to be explanted, resulting in limited availability for patients with 
unsuitable veins. Furthermore, a minimal invasive application was not tried or intended yet.  
Another concept was implemented within the Aneugraft® from ITGI Medical. This balloon 
expandable stent is covered by equine pericardium. By using a xenograft, the stent can be 
fabricated and stored until use and be available for patients without regard to their vessels. 
Nevertheless, it is not autologous and immunoreactions cannot be avoided completely. 
Additionally there is no endothelial lining. Still, the stents performed well in case of stenosis 
aneurysm and vessel perforation. The safety and feasibility for saphenous vein graft stenosis 
was evaluated in two clinical trials: SLEEVE I and II. So far the data did not show any signs of 
acute thrombosis(33). The long term outcome has to be awaited.  
Nevertheless, this trial shows the need for a covered stent. Covered stent can not only be 
used for stenosis but also for treatment of aneurysm and perforations of the vessel. 
By proving to withstand the blood flow also as interponate, the BioStent proved to 
withstand the blood flow. Therefore also the use for treatment of aneurysm and perforation 
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of vessels is promising. Using autologous tissue the body reaction is expected promising 
which is additionally perfected by the endothelial lining.  
In conclusion the BioStent is very promising in comparison to state of the art stents. 
Although further effort is needed on the stent structure for intra vascular placement, the 
tissue formation of the stent succeeded in the vascular system of sheep. 
Conclusions 
It is mainly accepted that one important cause of stenosis and restenosis is a missing or 
damaged endothelial layer(26). The nowadays used DES’s are still inhibiting vascular healing 
and endothelial growth(24, 25). A new method has to be addressed. Therefore the BioStent, 
a novel tissue engineered, autologous, endothelialized stent graft was developed to exclude 
the plaque and submit a functional EC-layer.  
The in vitro results examined a warp knitted stent as framework, as best for coverage and 
crimping. The dense structure with low forward elongation did not damage the tissue during 
crimping. For endothelialization the ECs were used in Passage 4, as consequence of a 
dedifferentiation test, showing a shift in morphology and gene expression for later passages. 
The in vivo tests disproved the used warp-of the knitted stent design as functional for stent 
application. The stent structure was not strong enough to completely expand inside the 
vessel. Therefore the stents were implanted as interponate for in vivo evaluation. The pre 
crimped BioStent proved to be implantable in carotid position over three months. 
Furthermore, the important crimping process could be performed without clinical relevant 
damage. The stent evidenced patency in four of five sheep over three months of planned 
implantation time. The tissue analysis showed healthy tissue formation and a confluent 
endothelial layer orientated to the blood flow.  
Although the results were very promising, the BioStent needs further improvement. One 
central matter is the stent structure which needs further development. First improvements 
were already addressed with better outcomes in radial force and bending stiffness but still 
the parameters are out of commercial range.  
Furthermore, to reach also patients for acute stenting, the production process needs to be 
shortened. The weak point is the long cultivation time for cell proliferation and conditioning. 
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By using a different scaffold, about two months could be saved. First test using ELR gels 
showed promising results for endothelialization. The gels are much stronger compared to 
fibrin gels and can be seeded with endothelial cells without supporting SMC/FB. 
Furthermore, the stiffness can be adjusted by concentration. Using stiffer gels would also 
allow the use of less stent struts, leading to new possibilities in stent structure. To increase 
the EC adhesion, cell adhesion molecules can be integrated in the gel. By this in a next step 
the endothelialization must be optimized for shorted preconditioning.  
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6 Appendix 
6.1 Protocol for staining of FACS samples 
1. Detache cells with accutase 
2. Adjust to 1*10
6
 cells/ml with PBS 
3. Centrifuge 1 ml at 500 x g for 5 min 
4. Waste supernatant 
5. Resuspend pellet in 10 µl of directly labelled antibody 
6. Incubate for 30 min at 4 °C 
7. Wash with 1ml PBS 
8. Centrifuge at 500 x g for 5 min 
9. Repeat step 7 + 8 twice 
10. Resuspend the pellet in 350 µl PBS 
11. Store on ice until measurement  
 
6.2 Protocol RNA isolation RNeasy Mini Kit 
1. Defreeze lyzed cells 
2. Add one volume of 70 % ethanol 
3. Transfer on the RNeasy Mini column, placed in a 2 ml collection tube  
4. Centrifuge at 10000  x g for 30 s  
5. Waste flow-through 
6. Add 350 µl RW1-buffer on column 
7. Centrifuge at 10000  x g for 30 s  
8. Waste flow-through 
9. Add 10 µl DNase I stock solution and 70 µl RDD buffer on the column 
10. Incubate for 15 min at RT 
11. Add 350 µl RW1 buffer on column 
12. Centrifuge at 10000 x g for 30 s  
13. Waste flow-through 
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14. Add 500 µl RPE buffer on the column 
15. Centrifuge at 10000 x g for 30 s 
16. Waste flow-through  
17. Add 500 µl of RPE buffer on column 
18. Centrifuge at 10000  x g for 30 s 
19. Waste flow-through and collection tube  
20. Place the spin column in a new 2 ml collection tube 
21. Centrifuge at 13000 x  g for 1 min (drying) 
22. Waste flow-through and collection tube 
23. Place column on fresh 1.5 ml collection tube 
24. Add 35 µl of 1:10 TE-buffer in the center of the membrane 
25. Incubate for 3 min at RT 
26. Centrifuge at 13000  x  g for 1 min 
27. Repeat steps 23) -26) before proceeding 
28. Store eluate on ice until measurement 
29. Measure RNA concentration by absorption at a wavelength of 260 nm using a 
spectrophotometer (NanoDrop 2000 - Thermo Scientific) and calculatie the quality by 
the absorbance ratio of 260/280. The quality of the RNA is good when this value is 
between 1.8 and 2 
30. Store at -20 °C or directly use for cDNA synthesis  
 
6.3 Protocol RNA isolation RNeasy Micro Kit 
1. Defreeze samples 
2. Wash with PBS 
3. Rinse the samples with 1 ml RLT-buffer (3x) 
4. Transfer lysate on the gDNA Eliminator spin column, placed in a 2 ml collection tube  
5. Centrifuge at 8000  x g for 30 s  
6. Remove column  
7. Add one volume of 70 % ethanol to flow through 
8. Transfer on a RNeasy MinElute spin column, placed in a 2 ml collection tube  
9. Centrifuge at 8000  x g for 30 s  
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10. Waste flow-through   
11. Add 700 µl RW1 buffer on the column 
12. Centrifuge at 8000  x  g for 30 s  
13. Waste flow-through 
14. Add 500 µl RPW buffer on the column 
15. Centrifuge at 8000  x  g for 30 s 
16. Waste flow-through  
17. Add 500 µl of 80 % ethanol 
18. Centrifuge at 8000  x  g for 2 min 
19. Waste flow-through and collection tube  
20. Place the spin column in a new 2 ml collection tube   
21. Centrifuge at 16000  x  g for 5 min 
22. Waste flow-through and collection tube 
23. Place column on fresh 1.5 ml collection tube 
24. Add 14 µl of 1:10 TE-buffer in the center of the membrane 
25. Incubate for 3 min at RT 
26. Centrifuge at 16000 x g for 1 min 
27. Repeat steps 23. -26.  
28. Store eluate on ice until measurement 
29. Measure RNA concentration by absorption at a wavelength of 260 nm using a 
spectrophotometer (NanoDrop 2000 - Thermo Scientific) and calculation the quality by 
the absorption ratio of 260/280. The quality of the RNA is good when this value is 
between 1.8 and 2 
30. Store at -20 °C or use directly for cDNA synthesis  
 
6.4 Protocol for staining of platelets 
1. Wash stents with PBS for 5min      
2. Fix in methanol at -20 °C for 10 min 
3. Wash 3 x 5 min with wash buffer (WB) (0.1 % Triton in PBS)   
4. Block with 500 µl per well 5 % goat serum in WB for 30 min 
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5. Add primary antibody diluted 1:100 in WB 500µl per well at 37 °C for 30 min  
6. Wash 3 x 5 min with WB 
7. Add secondary antibody in WB 1:400 500 µl per Well at 37 °C for 30 min   
8. Wash 3 x 5min with WB 
9. Stain with DAPI 500µl per well for 5min       
10. Wash 3 x 5min with WB 
11. Keep the stents in PBS for imaging 
 
6.5 Buffer and Media 
Bioreactor medium 
500ml DMEM  
160 mg Ascorbic Acid (light sensitive) dissolved in DMEM, and sterile filtrated 
50ml FCS  
5ml ABM  
888µl (1000mg/10ml) Tranexcaic acid (endconcentration of 1mM) 
 
Transport buffer  
40 g NaCl (Sigma, S9625) 
1.5 g KCl (Merck, 1.04936.0500)  
11.9 g Hepes (Sigma, H-3784) 
10 g D-Glucose (Merck, 1083370250) 
500 ml Aqua dest 
 
TBS 
17.44 g Tris HCl (Sigma, T3253) 
2.56 g Tris Base (Sigma, T6066) 
32.0 g NaCl (Sigma, S9625) 
0.8 g KCl (Merck, 1.04936.0500) 
4 l Aqua dest 
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6.6 Materials  
Product Company Order Nr. 
Acetic Acid p.a. 99,8% Sigma 33209 
Alexa Fluor 488 goat anti mouse Invitrogen A11001 
Alexa Fluor 488 goat anti rabbit Invitrogen A11008 
Alexa Fluor 594 goat anti mouse Invitrogen A11005 
Alexa Fluor 594 goat anti rabbit Invitrogen A11012 
Anti CD-31 (PECAM-1) Mab Sigma  P8590 
Antibiotic/ Antimycotic Invitrogen 15240062 
BSA Sigma A 9647-100g 
Cell culture flask T 175 Greiner 660175 
Cell culture flask T 25 Greiner 19000137 
Cell culture flask T 75 Greiner 658175 
Chloroform  Merck 1.024.452.500 
Collagen 1 (Primary Antibody) acris R1038 
Cryo-tubes Greiner 122279 
Cyklokapron Injektionsolution 1000 mg Pfizer PZN 523241 
DAPI Sigma D 9564 
Dextran sulfate Na-salt 5 kDa D7037 Sigma 
Dextran sulfate Na-salt 500 kDa D8906 Sigma 
Dialyze membrane Spectra Por 1 MWCO 6000-
8000 20,4 mm VWR 734-0665 
Dialyze membrane Spectra Por 1 MWCO 6000-
8000 31,8 mm VWR 734-0667 
DMEM Invitrogen 21885-108 
DMSO Sigma D2650 
Dulbecco's PBS Invitrogen 14190169 
Endothel Cell Growth Medium 2 with 
supplements (EBM 2) Lonza CC3162 
Endothel Supplements  PAA U05-012 
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Endothelial basal medium  PAA U15-011 
Falcon Tubes 15ml VWR 734-0451  
Falcon Tubes 50ml VWR 734-0448 
FBS (foetal Bovine Serum) Invitrogen 10270-106 
Fibrinogen from human Plasma, Calbiochem VWR 341576-1 
Fibronectin Tebu-bio 2003-1MG 
Flourescent Mounting Medium Dako S3023 
Fluoreszenzlampe für Observer  Osram HB0 103W/2 
Gelatine Sigma G9391 
Glutamax  Invitrogen 35050038 
Gore Tex® Stretch Vascular Graft 6 mm / 90 cm Gore ST0609 
Hepes sodium salt Sigma H-3784 
Kollagen 3 (Primary Antibody) acris R1040 
L-Ascorbic acid 2-phosphate  Sigma A8960 
Mayers Hämalaun Merck 1.092.490.500 
Normal Goat Serum Dako X0907 
Pressure detector PVB Codan DPT-9300 
Propanol-2 ( = Isopropanol) VWR 20.842.330 
Smooth Muscle Actin (primary antibody) Sigma A2547 
Suturematerial: Prolene BV1 7-0, 75 cm Ethicon F 1851 
Suturematerial: Vascufil coated monofil 6-0 Covidien 8886-4710-11V 
Thrombin from bovine Plasma Sigma T4648 
Triple Flasks VWR 734-2001 
Trizma Base (Tris Base) Sigma T6066 
Trizma Hydrochloride (Tris HCl) Sigma T3253 
Trypsin EDTA Pan Biotech P 10-023100 
Tube for pump ismatec MF 0013 
Tube: Silikon Platin  ismatec SC 0584 
vWF (primary Antibody) Dako A0082 
Well Microplates 96 nunc 260836 
Well Microplates 96 white Nunc 136101 
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Well Microplatte 96 schwarz, klarer Boden Greiner 675090 
Well Plates 96 Greiner 655180 
Well-Plates 12 Greiner 665180 
Well-Plates 24 Greiner 662160 
Well-Plates 48 Greiner 677180 
Well-Plates 6 Greiner 657160 
XTT Roche Cat. 11465015001 
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